Stanislaw R. Burzynski MD, PhD and Founder

About The Doctor

Dr. Burzynski, a nationally and internationally recognized physician/investigator, pioneered the use of biologically active peptides for the treatment of cancer. In 1967, at the age of 24, Dr. Burzynski graduated first in his class of 250 students from the Medical Academy in Lublin, Poland. It was at this time that he identified naturally occurring human peptides, which were deficient in cancer patients. He concluded that these peptides played a role in preventing the growth of cancer cells. In 1968, he earned a PhD degree and became one of the youngest physician/investigators in Poland to hold both a MD and PhD degree.

Between 1970 and 1977, he received funding from the National Cancer Institute (NCI) for his work as a Principal investigator and Assistant Professor at the Baylor College of Medicine in Houston, TX. During this time he authored/coauthored numerous publications, including those detailing his work on naturally occurring human peptides and their effect on cancer – some of which were co-authored by investigators associated with the M.D. Anderson Cancer Center or the Baylor College School of Medicine. In May 1977, Dr. Burzynski received a Certificate of Appreciation from the Baylor College of Medicine that acknowledged his contributions to the ‘Advancement of Medical Education, Research, and Health Care’.

In 1977 the Burzynski Clinic was established in Houston, TX. Since then, more than 10,000 patients have received treatment at the clinic, including more than 2,300 cancer patients who have been treated in FDA reviewed and Institutional Review Board (IRB) approved clinical trials program of Antineoplastons, investigational agents that derived from Dr. Burzynski’s early investigations of naturally occurring human peptides. Currently, new FDA-reviewed Phase II and III clinical studies utilizing Antineoplastons are awaiting funding approval prior to patient enrollment.

Dr. Burzynski has extensive experience treating cancer with combinations of targeted agents and immunotherapy, and the drug phenylbutyrate (PB), which targets multiple genetic abnormalities simultaneously.

Dr. Burzynski is the author/co-author of over 300 scientific publication/presentations. He has collaborated with investigators at the NCI, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, and the University of Turin Medical School in Italy, among others. He is a member of several prestigious organizations, including the American Medical Association, American Association of Cancer Research (AACR), American Society of Clinical Oncology, the Society for Neuroscience, the Society for Neuro-oncology, the Royal Medical Association (U.K.), and the Academy of Medical Ethics. As of June 2015, he held 245 patents in 35 countries covering his scientific inventions.

CURRICULUM VITAE

Stanislaw R. Burzynski, M.D., Ph.D.

ACADEMIC TRAINING, CERTIFICATION AND LICENSURE

Texas State Board of Medical Examiners

License to Practice Medicine, 1973

Baylor College of Medicine, Houston, Texas

ECFMG Certificate, 1971

Medical Academy, Lublin, Poland

M.D. with Distinction, 1967

Ph.D. (Biochemistry), 1968

POSITIONS HELD

Visiting Professor of Neuro-Oncology, Capital University in Beijing
Beijing, China, 2012 to 2017

Visiting Professor of Neuro-Oncology, Beijing Tiantan Hospital
Beijing, Tiantan, 2012 to present

Visiting Professor, Linyi People’s Hospital
Linyi City, China, 2012 to present

President, Burzynski Research Institute Inc.
Houston, TX, 1983 to present

Laboratory Director, Burzynski Clinic Laboratory
Houston, TX, 1979 to present

President, Burzynski Clinic
Houston, TX, 1977 to present

Assistant Professor, Baylor College of Medicine
Houston, Texas, 1972-1977

Research Associate, Baylor College of Medicine
Houston, Texas, 1970-1972

Intern and Resident, Medical Academy, Internship in the Departments of Surgery, Internal Medicine,
Pediatrics, Obstetrics and Gynecology, and Residency in the Department of Internal Medicine
Lublin, Poland, 1967-1970

Teaching Assistant, Medical Academy, Department of General Chemistry
Lublin, Poland, 1962-1967

Research Worker, Medical Academy, Department of General Chemistry
Lublin, Poland, 1961-1962

SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS

American Academy of Anti-Aging Medicine

American Association for Advancement of Science

American Association for Cancer Research

American Association of Pharmaceutical Scientists

American Chemical Society

American Medical Association

European Association for Neuro-Oncology

Harris County Medical Society

New York Academy of Sciences

Society for Neuro-Oncology

Society for Neuroscience

Texas Medical Association

The Royal Society of Medicine (U.K.)

The Society of Sigma Xi

World Medical Association

World Society of Anti-Aging Medicine

RESEARCH SUPPORT

National Cancer Institute Grantee, 1974-1977

Baylor College of Medicine Grantee, 1976

West Foundation Grantee, 1975

Medical Academy (Lublin, Poland) Grantee, 1962-1967

HONORS AND AWARDS

Lifetime Achievement Award from The Truth About Cancer, Nashville, TN, December 2015

Lifetime Achievement Award from the Academy of Comprehensive Integrative Medicine, Ft. Worth, TX, March, 2012

The Linus Pauling Award, October, 2008, ACAM

The Linus Pauling Award, February, 2008, Orthomolecular Health-Medicine

The Order of Merit of the President of Poland – Officer’s Cross, October, 2004

Decoration of Polish Medical Association, November, 2001

The Order of Saint Brigida – Grand Cross with Star, November, 2001

The Order of Saint Stanislas – Grand Cross with Star, November, 2000

The Order of Reconciliation – November, 2000

The Cross Virtus Nobilitat, June, 1999

The Wisdom Award of Honor, December, 1998

The Medal of the President of City of Lublin, Poland, December, 1998

The Order of Saint Stanislas- Commander’s Cross with Star, December, 1997

The Lady Liberty Award, July, 1997

The Gold Medal from the American Institute of Polish Culture for outstanding achievements in the field of medicine and discovery of anti-cancer drugs antineoplastons, Miami, FL, February, 1997

The Medal “Heart for Hearts” for saving human lives, Lublin, Poland, August, 1997

The Memorial Medal of Zamoyski’s Lyceum in appreciation of outstanding contribution to increase scientific ranking of the school, Lublin, Poland, November, 1997

The Heritage Award by Polish American Congress in recognition of extraordinary achievement in the research, treatment, and prevention of cancer, Chicago, IL, October, 1993.

Special Medal from the Polish government’s Institute for Drug Research and Control for achievement in the field of cancer research, Bialvstok, Poland, September, 1989

Honorable Membership in the Academia del Medeterraneo, Rome, Italy, 1984

Recipient of commendation for Dedicated Service and for Personal Contribution made in the

Advancement of Medical Education, Research and Health Care, Baylor College of Medicine, Houston, TX, April, 1977

Recipient of Medical Doctor Diploma with Distinction, Medical Academy, Lublin, Poland, 1967

Co-winner of the prize for best paper presented at the 7^th Conference of Polish Medical Student Research

Societies, Poznan, Poland, 1966.

The Hereditary Title of Count

More Information About Stanislaw R. Burzynski MD, PHD

HONORABLE BIOGRAPHY: Biography published in Marquis, Who’s Who in the World, 8^th through 26^th editions

Biography published in Marquis, Who’s Who in America, 51^st through 65^th editions

Biography published in Marquis, Who’s Who in Science and Engineering, 2^nd through 6^th editions

Biography published in Marquis, Who’s Who in Medicine and Healthcare, 1^st through 6^th editions

Biography published in Marquis, Who’s Who in Emerging Leaders in America, 1^st edition

Biography published in Marquis, Who’s Who Frontiers of Science and Technology, 2^nd edition

Biography published in American Men and Women of Science, 13^th Edition, Jacques Catell Press
CHAIRMAN OF SCIENTIFIC SESSIONS AT INTERNATIONAL MEETINGS: Co-Chairman, BIT’s 8^th Annual World Congress of NeuroTalk-2017, Barcelona, Spain, 2017

Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM), Dubai, UAE, 2008

1^st Anti-Aging International Symposium and Exposition, Tokyo, Japan, 2006

International Conference in Integrative Medicine, Seattle, Washington, U.S.A, 1999

Comprehensive Cancer Care I Conference, Washington, D.C., U.S.A., 1998

18^th International Congress of Chemotherapy, Stockholm, Sweden, 1993

17^th International Congress of Chemotherapy, Berlin, Germany, 1991

9^th International Symposium on Future Trends in Chemotherapy, Geneva, Switzerland, 1990

10^th Congress of the Polish Pharmacological Society, Bialystok, Poland, 1989

8^th International Symposium on Future Trends in Chemotherapy, Tirrenia, Italy, 1988

10^th International Congress of Pharmacology, Sydney, Australia, 1987
INVITED LECTURES (given since 1988): “Precision therapy of glioblastoma.” Keynote Speaker. Presented at BIT’s 8^th Annual World Congress of NeuroTalk-2017, Barcelona, Spain, May 22-24, 2017.

“Cancer treatment in the Information Age. The cure is in sight.” Keynote Speaker. Presented at the Truth About Cancer: A Global Quest, Nashville, TN, October 14, 2016.

“Personalized targeted cancer therapy revolution.” Keynote Speaker. Presented at the 8^th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo, and the 2^nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 25, 2013.

“Clinical trials with Antineoplastons. Long-term survival and quality of life.” Keynote Speaker. Presented at the 8^th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo, and the 2^nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 26, 2013.

“Antineoplastons, chemistry, mechanism of action, design, and criticism of clinical trials.” Keynote Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Prospective clinical trials with antineoplastons for inoperable brain tumors in children.” Keynote Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Phase 2 prospective clinical trials for inoperable brain tumors in adults.” Keynote Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in children.” Keynote Speaker. Presented at the Philippine Society of Pediatric Oncology 2012 Annual Convention in Ilo ilo, Philippines, October 27, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Update.” Presented at the Makati Medical Center in Manila, Philippines, October 25, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in children.” Keynote Speaker. Presented at St. Lukes Medical Center in Manila, Philippines, October 24, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in adults.” Keynote Speaker. Presented at St. Lukes Medical Center in Manila, Philippines, October 24, 2012.

“Phase II clinical trials of Antineoplastons in pediatric brain tumors and adult brain tumors.” Keynote Speaker. Presented at the “2012 Shanghai World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo (A4MC-2012),” at the Shanghai World Expo Exhibition & Convention Center in Shanghai, China, October 18, 2012.

“The future is full of hope: Cancer treatment based on genomic testing.” Keynote Speaker. Presented at the “Hope for the Hopeless Conference,” at the American Airlines Training & Conference Center in Ft. Worth, TX, March 9, 2012.

“Epigenomic Approach to Cancer Treatment.” Keynote Speaker. Presented at the “45^th Annual Meeting of the American Academy of Environmental Medicine,” San Diego, CA, October 21, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.” Keynote Speaker. Presented at the “10^th Scientific Meeting of the Japanese Society of Anti-Aging Medicine,” Kyoto, Japan, June 12, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.” Presented for 50 doctors at Keiko University, Tokyo, Japan, June 9, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.” Presented for 10-20 doctors at Tokai University, Tokyo, Japan, June 8, 2010.

“Antineoplastons.” Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

“Mechanisms of Anti-Tumor Activity in Synthetic Antineoplastons.” Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

“Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials.” Presented at the “Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM),” Dubai, UAE, 2008

“Antineoplastons and Targeted Gene Therapy.” Presented at the “ACAM Las Vegas,” Las Vegas, Nevada, October 15-19, 2008

“Genome, Epigenome and Aging.” Presented at the “First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“Personalized Cancer Treatment in Genomics Era.” Presented at the “First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“Anti-Aging Peptides – A New Frontier in Healing.” Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“Antineoplaston Peptides in Treating Cancer.” Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“Personalized Cancer Treatment.” Presented at the “2007 Total Health and Recovery Expo” in The Woodlands, Texas, October 20, 2007

“Cancer Treatment in Genomics Era.” Hosted by the Lions Health First Foundation, at the Hilton in Las Vegas, Nevada, September 15, 2007

“The Genetic Solution for Anti-Aging.” Presented at the “Healthy Directions Conference,” hosted by Dr. Julian Whitaker at the Marriott Westchase in Houston, Texas, January 6, 2007

“The Genetic Solution for Anti-Aging.” Presented at 11^th Cruising for Health and Wealth, January 2006

“New Cancer Treatments and Anti-Aging Regimens.” Presented at the “Polish Club of Leisure World,” in Laguna Woods, California, March 13, 2005

“Mechanizmy I profilaktyka genetycznego starzenia (Mechanisms and Prevention of Genetic Aging).” Presented at the “Ogolnoeuropejska Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Neurologicznego,” in Lublin, Poland, September (wrzesień) 22-25, 2004

“Regulation of Gene Expression in Cancer and Aging.” Presented at “Innovations in Complementary/Integrative Healthcare,” in Phoenix, Arizona, September 5-7, 2003

“Treatment of Cancer with Antineoplastons: Effect on Genes and Protein Metabolism.”
Presented at the “12^th Annual Scientific Symposium,” in Orlando, Florida, August 27-31, 2003

“Gene Silencing in Cancer and Aging”. Presented at Graduation Ceremony: Ultrasound Diagnostic

School, November 15, 2002

“Antineoplaston Treatment of Cancer – Results of American and Japanese Clinical Trials.” Presented at

ABEIM – A Cancer Symposium, Fort Worth, Texas, 2002

“Antineoplaston Cancer Treatment – Theory and Results”; “Cancer and Aging – The Connection”;

“Controlling the Key Aging Process of Methylation and Acetylation with the New Category of Anti-Aging Compounds and Antineoplastons.” Presented at the 6^th International Symposium on Anti-Aging Medicine, Costa Rica, Los Suenos, August 23-24, 2002

“Treatment and Prevention of Cancer with Antineoplastons,” Presented in Santiago, Chile, July 3, 2002

“Antineoplastons –Theory and Treatment,” Presented at Seminar for Physicians: Sanoviv, Baja

California, June 13, 2002

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1.” Presented at Hyman-Newman

Institute for Neurology and Neurosurgery, Beth Israel Hospital, New York, August 22, 2001

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1”, Presented at Therapeutic Good

Administration (TGA) of Australia, Canberra, Australia, July 17, 2001

“Antineoplastons.” Presented at Polish Medical Association, Warsaw, Poland, November 22, 2000.

“Treatment of Cancer with Antineoplastons.” Presented at Symposium organized by People Against Cancer in Stuttgart and Munich, Germany, for General Audience, November, 1999

“Antineoplastons: A Breakthrough in Cancer Therapy.” Presented at Manila Doctors Hospital, Manila, The Philippines, November 9, 1998

“The New Breakthrough in Cancer.” Presented at Marian Cancer Foundation, Manila, The Philippines, November 6, 1998

“Antineoplastons.” Presented at “Surviving Cancer.” Westminster Central Hall, London, U.K.,

November 15, 1997

“Antineoplastons: Theory and Clinical Trials.” Presented at Medical Academy, Lublin, Poland,

November 7, 1997

“Biochemical Defense System.” Presented at Medical Academy, Lodz, Poland, July 24, 1992

“Treatment of AIDS and HIV Infection with Antineoplastons AS2-1”. Presented at Search Alliance, Los

Angeles, California, November 20, 1991

“Cancer, AIDS and the other Immune System”. Presented at Foundation for the Advancement of Innovative Medicine, New York, NY, October 26, 1991

“Antineoplastons.” Presented at World Research Foundation Congress, Los Angeles, California,

October 7, 1990

“Antineoplastons—New Methods of Cancer Treatment.” Presented at Polish Pharmacological Society,

Lublin, Poland, August 29, 1989

“Clinical Results of Antineoplaston Therapy.” Presented at Kurume University School of Medicine,

Kurume, Japan, April 9, 1988

“Mechanism of Action of Antineoplaston A10 and Experimental Data.” Presented at Kurume University

School of Medicine, Kurume, Japan, April 8, 1988

“Isolation, Purification and Synthesis of Antineoplastons.” Presented at Kurume University School of

Medicine, Kurume, Japan, April 8, 1988
EDITORIAL POSITIONS: Reviews on recent clinical trials, Bentham Science Publishers, Editor-In-Chief.
BOOK CHAPTERS, MONOGRAPHS AND ARTICLES BY S.R. BURZYNSKI AND ASSOCIATES: Date: 2024

Title: Recurrent Desmoplastic Infantile Ganglioglioma Treated with Antineoplastons: Partial Response and Overall Survival of > 11.8 Years in a Ten-Month-Old Female.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Int J Brain Disord Treat 10:050. doi.org/10.23937/2469-

5866/1410050

Date: 2024

Title: Recurrent/Disseminated Choroid Plexus Carcinoma: Overall Survival of > 23.6 Years in a One-Year and Nine-Month-Old Female Treated with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Journal of Medical Research and Case Reports 6(1). DOI:

10.5281/zenodo.11387006

Date: 2024

Title: Recurrent Pilocytic Astrocytoma: Treatment with Antineoplastons, Complete Response, and > 27 Years Overall Survival

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Recent Adv Clin Trials. 2024; 4(1); 1-7.

Date: 2023

Title: Recurrent Medulloblastoma:  Complete Response and > than 21 Years and Five Months Overall Survival in a One-Year and Seven-Month-Old Male Treated with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Journal of Oncology Research Review & Reports. 2023 Vol 4(4): 1-6;

SRC/JONRR-186

Date: 2023

Title: Inoperable Optic Pathway Glioma: A Seven-Year-Old Male with >35 Years Overall Survival Following Treatment with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: European Journal of Clinical Medicine, 4(5), 9–14. https://doi.org/10.24018/clinicmed.2023.4.5.312

Date: 2023

Title: Persistent pineoblastoma: complete response and > 26 years overall survival in a ten-month-old female treated with antineoplastons.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Biomed Res Clin Prac, 2023.

DOI: 10.15761/BRCP.1000227

Date: 2023

Title: Newly diagnosed Anaplastic Astrocytoma: > 23 Year Survival in a 31-Year and 11-Month-Old Female Treated with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Neurol Neurosci. 2023;4(2):1-6.

DOI: 10.33425/2692-7918.1051

Date: 2022

Title: Newly Diagnosed Glioblastoma: Partial Response and > 27 Years Overall Survival in 37-Year-Old Male Treated with Antineoplastons (Treatment of Glioblastoma with Antineoplastons).

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Recent Adv Clin Trials. 2022; 2(2): 1-7.

DOI: 10.33425/2771-9057.1018

Date: 2022

Title: Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons).

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Cancer Stud Ther J Volume 7(3): 1–6.

DOI: 10.31038/CST.2022733

Date: 2022

Title: Outcomes in Four Children with Persistent, Recurrent, and Progressive Gangliogliomas Treated in Phase II Studies with Antineoplastons A10 and AS2-1.

Authors: Burzynski, S., Burzynski, G., Janicki, T., Beenken, S.

Published By: Neurology and Neuroscience Volume 3(3): 1–9.

DOI: 10.33425/2692-7918.1036

Date: 2022

Title: Newly-Diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and > 22 Years Survival in a Six Year and Nine-Month-Old Female Treated with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G., Janicki, T., Beenken, S.

Published By: International Journal of Clinical Oncology and Cancer Research Volume 7(3): 76–82.

DOI: 10.11648/j.ijcocr.20220703.15

Date: 2022

Title: Recurrent and Progressive Ganglioglioma in an 11-Year-Old Male Treated with Antineoplastons A10 and AS2-1: A Case Report.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T.J., Weaver, R.A.

Published By: Biomedical Journal of Scientific & Technical Research Volume 37(1): 1–6.

DOI: 10.26717/BJSTR.2022.37.005999

Date: 2022

Title: Twenty-Two Year Survival in 15-Year-Old Female with a Recurrent Posterior Fossa Ependymoma Treated with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Oncology Clinics and Research Volume 5(1): 99–105.

Date: 2022

Title: A 25-Year-Old Female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons.

Authors: Burzynski, S.R., Burzynski, G., Janicki, T., Beenken, S.

Published By: International Journal of Clinical Oncology and Cancer Research Volume 7(1): 1–7.

DOI: 10.11648/j.ijcocr.20220701.11

Date: 2021

Title: Diffuse Intrinsic Pontine Glioma in an 11-Year-Old Female Treated with Antineoplastons: Complete Response and >25 Years Survival.

Authors: Burzynski, S., Burzynski, G., Janicki, T., Beenken, S.

Published By: Pediatrics and Neonatal Medicine Volume 1(2): 1–5.

DOI: 10.33425/2768-0363.1010

Date: 2021

Title: Long-Term Survival (23 Years) in a 26-Year-Old Male after Antineoplaston Therapy for a Progressive, Diffuse Intrinsic Pontine Glioma: A Case Report.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: International Journal of Brain Disorders and Treatment Volume 6: 038.

DOI: 10.23937/2469-5866/1410038

Date: 2021

Title: Resolution of Clinical Signs, a Complete Response, and Long-Term Survival (>23 Years) in a 3 and ½ Month Female with a Newly Diagnosed Diffuse Intrinsic Pontine Glioma Treated with Antineoplastons.

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S., Beenken, S.

Published By: Biomedical Research and Clinical Practice Volume 6: 1–6.

DOI: 10.15761/BRCP.1000220

Date: 2021

Title: Long-Term Survival (27.7 Years) Following IV Antineoplaston Therapy (ANP) in a 36-Year-Old Female with a Progressive Diffuse Intrinsic Pontine Glioma (DIPG).

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S., Beenken, S.

Published By: International Journal of Radiology and Imaging Technology Volume 7(1): 1–6.

DOI: 10.23937/2572-3235.1510073

Date: 2019

Title: Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T., Beenken, S.

Published By: Cancer and Clinical Oncology; Vol.8, No. 1; 2019.

DOI: 10.5539/cco.v8n1p1

Date: 2017

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Brain Tumors. Final Report (Protocol BT-10)

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.

Published By: Journal of Cancer Therapy Volume 8(2): 15–26.

DOI: 10.4236/jct.2017.82015

Date: 2017

Title: Antineoplastons A10 and AS2-1 in the Treatment of Children with Optic Pathway Glioma: Final Report for Protocol BT-23

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S.

Published By: Cancer and Clinical Oncology Volume 6(1): 25–31.

DOI: 10.5539/cco.v6n1p25

Date: 2016

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S.

Published By: Journal of Cancer Therapy Volume 7(12): 837–850.

DOI: 10.4236/jct.2016.712083

Date: 2016

Title: Primary CNS Tumors and Leptomeningeal, Disseminated and/or Multicentric Disease in Children Treated in Phase II Studies with Antineoplastons A10 and AS2-1

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S.

Published By: Cancer and Clinical Oncology Volume 5(2): 38–45.

DOI: 10.5539/cco.v5n2p38

Date: 2015

Title: A Case of Sustained Objective Response of Recurrent/Progressive Diffuse Intrinsic Pontine Glioma with Phenylbutyrate and Targeted Agents.

Authors: Burzynski, S.R., Burzynski, G.S., Brookman, S.

Published By: Journal of Cancer Therapy Volume 6(1): 1–4.

DOI: 10.4236/jct.2015.61006

Date: 2015

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Primary Brain Tumors—Final Report (Protocol BT-09)

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S.

Published By: Journal of Cancer Therapy Volume 6(12): 1161–1172.

DOI: 10.4236/jct.2015.612116

Date: 2015

Title: Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S.

Published By: Cancer and Clinical Oncology Volume 4(2): 41–46.

DOI: 10.5539/cco.v4n2p41

Date: 2015

Title: Long-Term Survival (Over 20 Years), Complete Response, and Normal Childhood Development in Medulloblastoma Treated with Antineoplastons A10 and AS2-1

Authors: Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca, J.F.

Published By: Journal of Neurology & Stroke Volume 2(3): 1–6.

DOI: 10.15406/jnsk.2015.02.00054

Date: 2015

Title: Complete response and Long-term survival (>20 years) of a child with tectal glioma: A case report.

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T.J., Marszalek, A.

Published By: Pediatr Neurosurg

DOI: 10.1016/j.pediatrneurol.2012.07.004

Date: 2015

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (Protocol BT-11)

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S., Marszalek, A.

Published By: Journal of Cancer Therapy Volume 6(4): 334–344.

DOI: 10.4236/jct.2015.64036

Date: 2015

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Newly-Diagnosed Anaplastic Astrocytoma—Final Report (Protocol BT-08)

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S., Marszalek, A.

Published By: Cancer and Clinical Oncology Volume 4(1): 28–35.

DOI: 10.5539/cco.v4n1p28

Date: 2015

Title: Long-Term Survival Over 21 Years and Pathologically Confirmed Complete Response in Pediatric Anaplastic Astrocytoma: A Case Report

Authors: Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca, J.F.

Published By: Journal of Neurology & Stroke Volume 2(6): 1–6.

DOI: 10.15406/jnsk.2015.02.00072

Date: 2015

Title: A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients with Recurrent Anaplastic Astrocytoma—Final Report (Protocol BT-15)

Authors: Burzynski, S.R., Janicki, T., Burzynski, G.S.

Published By: Cancer and Clinical Oncology Volume 4(2): 13–19.

DOI: 10.5539/cco.v4n2p13

Date: 2014

Title: Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: a case report.

Authors: Burzynski, G.S., Janicki, T.J., Marszalek, A.

Published By: Neuro-Oncology 2014; vol.16 (Suplement 5)     v175-v177,

DOI:10.1093

Date: 2014

Title: Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: a case report.

Authors: Burzynski, S.R., Burzynski, G.S.

Published By: Neuro-Oncology 2014; vol.16 (Suplement 5); v11

Date: 2014

Title: Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.

Published By: Journal of Cancer Therapy Volume 5(13): 1288–1305.

DOI: 10.4236/jct.2014.513128

Date: 2014

Title: Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential Strategy for Improved Survival

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.

Published By: Journal of Cancer Therapy Volume 5(12): 1145–1163.

DOI: 10.4236/jct.2014.512113

Date: 2014

Title: Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for Improved Survival

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.

Published By: Journal of Cancer Therapy Volume 5(12): 1127–1144.

DOI: 10.4236/jct.2014.512116

Date: 2014

Title: Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.

Published By: Journal of Cancer Therapy Volume 5(14): 1311–1324.

DOI: 10.4236/jct.2014.514144

Date: 2014

Title: A Phase II study of Antineoplaston A10 and AS2-1 in patients with brainstem gliomas Final report (Protocol BT-11).

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.

Published By: Neuro-Oncology 2014; vol.16 (Suplement 5); v16

Date: 2014

Title: Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report.

Authors: Janicki T.J., Burzynski G.S., Burzynski S.R.

Published By: Neuro-Oncology 2014; 16 (suppl. 5): v14-15.

Date: 2014

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21)

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S.

Published By: Journal of Cancer Therapy Volume 5(10): 946–956.

DOI: 10.4236/jct.2014.510100

Date: 2014

Title: Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival

Authors: Burzynski, S.R., Burzynski, G.S., Janicki, T.J.

Published By: Journal of Cancer Therapy Volume 5(10): 957–976.

DOI: 10.4236/jct.2014.510101

Date: 2014

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent, Refractory or Progressive Primary Brain Tumors—Final Report (Protocol BT-22)

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S.

Published By: Journal of Cancer Therapy Volume 5(10): 977–988.

DOI: 10.4236/jct.2014.510102

Date: 2014

Title: The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme

Authors: Burzynski, S.R., Patil, S.S.

Published By: Journal of Cancer Therapy Volume 5(10): 930–946.

DOI: 10.4236/jct.2014.510099

Date: October 2014

Title: Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Glioma

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.

Published By: Journal of Pediatric Hematology/Oncology Volume 36(7): e433–e439.

DOI: 10.1097/MPH.0000000000000218

Date: 2014

Title: Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020.

Authors: Janicki, T.J., Burzynski, S.R., Burzynski, G., Marszalek, A.

Published By: Neuro-Oncology 2014;16(Suppl. 1):i80.

Date: 2014

Title: A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High-Grade Glioma. Final Report (Protocol BT-06), and Review of Recent Trials

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.

Published By: Journal of Cancer Therapy Volume 5(6): 560–572.

DOI: 10.4236/jct.2014.56065

Date: 2014

Title: The Response and Survival of Children with Recurrent Diffuse Intrinsic Pontine Glioma Based on Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Glioma

Authors: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.

Published By: Child's Nervous System Volume 30(12): 2063–2072.

DOI: 10.1007/s00381-014-2401-z

Date: 2014

Title: Tratamentul multitintit cu antineoplastoni in glioamele cerebrale.

Authors: Burzynski, S.R.

Published By: Revista Buletinul Medicina Familiei (RBMF), Volume 1, Issue 27, January 2014.

Date: 2014

Title: Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer.

Authors: Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R.

Published By: Syst Biol Free Rad Antioxid 2014; 2325-2347;

DOI: 10.1007/978-3-642-30018-9.

Date: 2014

Title: Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017.

Authors: Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A.

Published By: Neuro-Oncology 2014;16(Suppl. 1):i44.

Date: 2014

Title: A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004.

Authors: Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A.

Published By: Neuro-Oncology 2014;16(Suppl. 1):i10.

Date: 2014

Title: Changed gene expression and longevity in honeybees (Apis mellifera) fed with phenylbultyrate- and phenylacetylglutaminate- supplamented diet.

Authors: Burzynski, S., Paleolog, J., Patil, S.

Published By: Medycyna Weterynaryjna  69 (12), 753-759, 2013.

Date: 2014

Title: Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report. N-089

Authors: Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A.

Published By: Neuro-Oncology 2013;15(Suppl. 3):iii120.

Date: 2013

Title: Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer.

Authors: Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R.

Published By: Drug Designing 2013;2(1):103.

DOI:10.4172/2169-0138.1000103

Date: 2013

Title: A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020.

Authors: Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A.

Published By: Neuro-Oncology 2013;15(Suppl. 3):iii103.

Date: 2013

Title: A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. NO-021.

Authors: Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A.

Published By: Neuro-Oncology 2013;15(Suppl. 3):iii103.

Date: 2013

Title: A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). NO-058.

Authors: Janicki, T.J., Burzynski, S.R, Burzynski, G.S., Marszalek, A.

Published By: Neuro-Oncology 2013;15(Suppl. 3):iii112.

Date: 2012

Title: Phenylacetylglutaminate in combination with Phenylbutyrate effectively inhibits growth of brain tumor cell In Vitro. P.003.

Authors: Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.

Published By: Neuro-Oncology 2012 Vol. 14 Supplement 3, iii16.

Date: 2012

Title: Phenylacetylglutaminate and Phenylacetate in combination Upregulate VDUP1, cause cell cycle blockade and Apoptosis in U87 Glioblastome cells.

Authors: Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K., Chittur, S.

Published By: Journal of Cancer Therapy, 2012, 3, 192-200.

DOI:10.4236/jct.2012.33028

Date: 2011

Title: The larval diet supplemented with sodium phenylacetylglutaminate influences the worker cuticle proteolytic system in honeybees (Apis mellifera).

Authors: Pateolog, J., Strachecka, A., Burzynski, S.R., Olszewski, K., Borsuk, G.

Published By: Journal of Apicultural  Science Vol.55 No. 2, 2011.

Date: 2011

Title: Treatment of esthesioneuroblastoma and nonsmall cell lung cancer with phenylbutyrate.

Authors: Burzynski, S.R., Nagy-Kubove, E.

Published By: Journal of Cancer Therapy 2011,2,518-522.

doi:10.4236/jct.2011.24071

Date: 2011

Title: Successful Treatment of Recurrent Triple-Negative Breast Cancer with Combination of Targeted Therapies.

Authors: Burzynski, S.R., Marquis, A., Nagy-Kubove, E., Janicki, T.

Published By: Journal of Cancer Therapy 2011, 2, 372-376.

DOI:10.4236/jct.2011.23050

Date: 2010

Title: A Phase II Study of Antineoplaston A-10 and AS-1 Injections in Children with Low-Grade Astrocytomas.

Authors: Burzynski, S.R., Weaver, R., Janicki, T.J., Szymkowski, B., Acelar, S., Burzynski, G.S.

Published By: Neuro-Oncology 2010; 12, ii95.

Date: 2010

Title: Targeting MicroRNAs in Glioma Cells with Antineoplastons.

Authors: Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.

Published By: Neuro-Oncology 2010; 12, iv10.

Date: 2010

Title: Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells.

Authors: Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.

Published By: Neuro-Oncology 2010; 12, ii87.

Date: 2010

Title: Preliminary Results of a Phase II Study of Antineoplastons A10 and AS2-1 (ANP) in Adult Patients with Recurrent Mixed Gliomas.

Authors: Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.

Published By: Neuro-Oncology 2010; 12, iv72.

Date: 2009

Title: Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.  Protocol BC-BT-11.

Authors: Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S.

Published By: Neuro-Oncology 2009, 11:951.

Date: 2009

Title: Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).

Authors: Weaver, R.A., Szymkowski, B., Burzynski, S.R.

Published By: Neuro-Oncology 2009; 11:923.

Date: 2009

Title: The Coming Pandemic of Liver Cancer.  In Search of Genomic Solutions.

Authors: Burzynski, S.R.

Published By: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI; 2009.

Date: 2009

Title: Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials.

Authors: Burzynski, S.R.

Published By: In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI; 2009. DOI:10.13140/2.1.4353.8888

Date: 2008

Title: Genomic approach to cancer treatment.

Authors: Burzynski, S.R.

Published By: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume X; 2008; 37-44.

Date: 2008

Title: Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report.

Authors: Burzynski, S.R., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B.

Published By: Neuro-Oncology 2008; 10:821.

Date: 2008

Title: Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma.

Authors: Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G.

Published By: Neuro-Oncology 2008; 10:1067.

Date: 2008

Title: Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells.

Authors: Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K.

Published By: Neuro-Oncology 2008; 10:786.

Date: 2008

Title: Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report.

Authors: Burzynski, S.R., Weaver, R.A., Janicki, T.J., Walczak, M., Szymkowski, B.G., Samuel, S.

Published By: Neuro-Oncology 2008; 10:450.

Date: 2008

Title: Geny Zycia. (The genes of life)

Authors: Burzynski, S.R.

Published By: Wydawnictwo Farmapress. Czasopismo Aptekarskie. Warszawa 2008.

Date: 2007

Title: Recent clinical trials in diffuse intrinsic brainstem glioma.

Authors: Burzynski, S.R.

Published By: Cancer Therapy 2007; 5, 379-390.

Date: 2007

Title: A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma.

Authors: Burzynski, S.R., Weaver, R., Szymkowski, B.

Published By: Neuro-Oncology 2007; 9:536.

Date: 2007

Title: Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells.

Authors: Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.

Published By: Neuro-Oncology 2007; 9:482.

Date: 2007

Title: The Genetic Solution for Anti-Aging. Chapter 10.

Authors: Burzynski, S.R.

Published By: In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007; 63-70.

Date: 2007

Title: Genetics of Brain Aging (I). Gene Silencing in Neurons. Chapter 11.

Authors: Burzynski, S.R.

Published By: In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007; 71-78.

Date: 2007

Title: Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas.

Authors: Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E.

Published By: Neuro-Oncology 2007; 9:206.

Date: 2007

Title: The breakthrough in therapy and prevention in medicine of 21st century (5).  Genes and aging of the neurons.  Geny a starzenie neuronow.

Authors: Burzynski, S.R.

Published By: Czasopismo Aptekarskie 2007; Nr 3 (159) 27-38.

Date: 2007

Title: The breakthrough in therapy and prevention in medicine of 21st century (4).  Time factor in biology and medicine.  Czynnik czasu w biologii i medycynie.

Authors: Burzynski, S.R.

Published By: Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36.

Date: 2007

Title: The breakthrough in therapy and prevention in medicine of 21st century (3). The medicine of aging population. Medycyna starzejacego sie spoleczenstwa.

Authors: Burzynski, S.R.

Published By: Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48.

Date: 2006

Title: The breakthrough in therapy and prevention in medicine of 21st century (2).  Epigenome and gene silencing.  Epigenom i wyciszanie genow.

Authors: Burzynski, S.R.

Published By: Czasopismo Aptekarskie 2006; Nr 12 (156) 29-36.

Date: 2006

Title: Targeted Therapy for Brain Tumors.

Authors: Burzynski, S.R.

Published By: Editor: Andrew V Yang. Brain Cancer Therapy and Surgical Interventions. New York (NY);  Nova Science Publishers, Inc. 2006; 77-111.

Date: 2006

Title: The breakthrough in therapy and prevention in medicine of 21st century (1). The medicine of genome an epigenome. Medycyna genomu i epigenomu.

Authors: Burzynski, S.R.

Published By: Czasopismo Aptekarskie 2006; Nr 11 (155) 45-52.

Date: 2006

Title: Age Management Treatments Which Target Silenced Genes.

Authors: Burzynski, S.R.

Published By: Redberry GW,  ed. Gene Silencing: New Research.  Nova Science Publishers, Inc. 2006.

Date: 2006

Title: Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1.

Authors: Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V.

Published By: Neuro-Oncology. 2006; 8:466.

Date: 2006

Title: Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report.

Authors: Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgopolov, V.

Published By: Neuro-Oncology. 2006; 8:439.

Date: 2006

Title: Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies.

Authors: Burzynski, S.R.

Published By: Pediatric Drugs 2006; 8: 167-178.

Date: 2006

Title: Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma.

Authors: Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B.

Published By: Integrative Cancer Therapies 2006; 5(1):40-47.

DOI:10.1177/1534735405285380

Date: 2006

Title: Master Clock of Life (II). How to Turn the Clock Back. In: American Academy of Anti-Aging Medicine.

Authors: Burzynski, S.R.

Published By: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics; Volume VIII 2006.

Date: 2006

Title: Phase II studies of  antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brain stem gliomas.

Authors: Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B.

Published By: Neuro-Oncology. 2006; 8:346.

Date: 2006

Title: Master Clock of Life (I). “Junk DNA.” and Promoters Regions as Major Components of the Clock.

Authors: Burzynski, S.R.

Published By: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics; Volume VIII 2006.

Date: 2005

Title: Gene silencing theory of aging: the clinical trial supporting the theory.

Authors: Burzynski, S.R.

Published By: Anti-Aging Therapeutics Vol VII, 2005; 39-46.

Date: 2005

Title: Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas.

Authors: Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G.

Published By: Neuro-Oncology. 2005; 7:300.

Date: 2005

Title: Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP.

Authors: Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B.

Published By: Neuro-Oncology. 2005; 7:299.

Date: 2005

Title: Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1.

Authors: Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.

Published By: Integrative Cancer Therapies 2005; 4(2): 168-177

Date: 2005

Title: Aging: Gene silencing or gene activation?

Authors: Burzynski, S.R.

Published By: Med Hypoth. 2005; 64, 201-208.

Date: 2004

Title: Mechanizmy i profilaktyka genetycznego starzenia.  Mechanisms and prevention of genetic aging.

Authors: Burzynski, S.R.

Published By: Neurologia I Psychiatria 2004; 4:1-8.

Date: 2004

Title: Antineoplastons In Dairy Products.

Authors: Burzynski, S.R., Ilkowska-Musial, E., Klimczak, M.W.,  Musial, L.

Published By: Journal of Applied Nutrition. 2004; 54; 1-8.

Date: 2004

Title: Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system.  A preliminary report.

Authors: Burzynski, S.R., Weaver, R. Bestak, M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Published By: Neuro-Oncology. 2004; 6: 427.

Date: 2004

Title: Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP). Preliminary results of phase II studies.

Authors: Burzynski, S.R., Weaver, R. Bestak, M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Published By: Neuro-Oncology. 2004; 6: 428.

Date: 2004

Title: Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma.

Authors: Burzynski, S.R., Weaver, R. Bestak, M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Published By: Neuro-Oncology. 2004; 6: 386.

Date: 2004

Title: Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme.

Authors: Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V.

Published By: Neuro-Oncology. 2004; 6: 384.

Date: 2004

Title: Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.

Authors: Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B.

Published By: Integrative Cancer Therapies. 2004; 3: 257-261.

DOI: 10.1177/1534735404267748

Date: 2004

Title: Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report.

Authors: Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.

Published By: Drugs R&D 2004; 5 (6): 315-326.

Date: 2004

Title: The Present State of Antineoplaston Research.

Authors: Burzynski, S.R.

Published By: Integrative Cancer Therapies 2004; 3: 47-58.

Date: 2003

Title: Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma.

Authors: Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M.

Published By: Drugs in R&D 2003; 4: 91-101.

DOI: 10.2165/00126839-200304020-00002

Date: 2003

Title: Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma. A preliminary report.

Authors: Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I.

Published By: Neuro-Oncology. 2003; 5: 358.

Date: 2003

Title: Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87.

Authors: Waldbillig, R., Burzynski, S.R.

Published By: Neuro-Oncology. 2003; 5: 309.

Date: 2003

Title: Theories of Aging. Old and New Concepts of the Aging Process.

Authors: Giampapa, V.C., Burzynski, S.R., Pero, R.

Published By: The Basic Principles and Practice of Anti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician. Vincent C. Giampapa (Ed.) 2003; 25-38

Date: 2003

Title: Gene Silencing - A New Theory of Aging.

Authors: Burzynski, S.R.

Published By: Med Hypoth. 2003; 60: 578-583.

Date: 2003

Title: Amino Acid Supplementation in Treatment of Cancer-Related Symptoms.

Authors: Burzynski, S.R., Maxwell L., Lewy, A.R., Janicki, T., Ilkowska-Musial, E., Baranowska, A.

Published By: Journal of Applied Nutrition 2003; 53:52-60.

Date: 2000

Title: Antineoplastons.

Authors: Burzynski, S.R.

Published By: In: Clinician's Complete Reference To Complementary/Alternative Medicine, Novey, D. W. (Ed.).  Mosby 2000; 496-507, St.Louis, USA.

Date: 2000

Title: The Best of Alternative Medicine.

Authors: Burzynski, S.R.

Published By: Townsend Letter for Doctors 2000; 200: 32.

Date: 1999

Title: A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors.

Authors: Burzynski, S.R., Conde, A.B., Peters, A., Saling, B., Ellithorpe, R., Daugherty, J.P., Nacht, C.H.

Published By: Clin. Drug Invest. 1999; 18: 1-10. https://doi.org/10.2165/00044011-199918010-00001

Date: 1999

Title: Efficacy of Antineoplastons A10 and AS2-1.

Authors: Burzynski, S.R.

Published By: Mayo Clin. Proc. 1999; 74: 641-643.

Date: 1998

Title: Antineoplastons in the treatment of malignant brain tumors.

Authors: Burzynski, S.R.

Published By: Anti-Aging Medical Terapeutics, vol. 2. Klatz RM., Goldman R. (Ed), Health Quest Publications 1998; 28-34,  Marina del Rey, Ca, USA.

Date: 1997

Title: Antineoplastons, oncogenes and cancer.

Authors: Burzynski, S.R.

Published By: Anti-Aging Medical Therapeutics, vol.1. Klatz RM, Goldman R. (Ed), Health Quest Publication 1997; Marina del Rey,  CA, USA.

Date: 1995

Title: Potential of antineoplastons in diseases of old age.

Authors: Burzynski, S.R.

Published By: Drugs & Aging. 1995; 7: 157-167.

Date: 1995

Title: Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells.

Authors: Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.

Published By: Cancer Letters 88 (1995); 88: 107-112.

Date: 1995

Title: The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.

Authors: Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z.

Published By: Drugs Exptl Clin Res. 1995;  21: 153-156.

Date: 1994

Title: The influence of antineoplaston A5 on the central dopaminergic structures.

Authors: Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.

Published By: Drugs Exptl Clin Res.  1994;  20:  161-167.

Date: 1993

Title: Immunosurveillance versus chemosurveillance.

Authors: Burzynski, S.R.

Published By: Post Nauk Med. 1993; 6: 260-262.

Date: 1993

Title: Antineoplastons. An Investigational Cancer Therapy.

Authors: Burzynski, S.R.

Published By: Townsend Letter for Doctors  1993; 3, 150-153

Date: 1992

Title: Novel differentiation inducers.

Authors: Burzynski, S.R.

Published By: Recent Advances in Chemotherapy.  Adam D.  (Ed), Futuramed Publishers.  1992;  Munich, Germany.

Date: 1992

Title: Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals.

Authors: Liau, M.C., Liau, C.P., Burzynski, S.R.

Published By: Internat J Exptl Clin Chemother. 1992; 5: 9-17.

Date: 1992

Title: Prevention of drug induced DNA hypermethylation by antineoplaston components.

Authors: Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.

Published By: Internat J Exptl Clin Chemother. 1992; 5: 19-27.

Date: 1992

Title: Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60.

Authors: Lee, S.S., Burzynski, S.R.

Published By: Recent Advances in Chemotherapy.  Adam D.  (Ed), Futuramed Publishers.  1992:  Munich, Germany.

Date: 1992

Title: Prevention of drug-induced DNA hypermethylation by antineoplastons.

Authors: Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.

Published By: Recent Advances in Chemotherapy.  Adam D.  (Ed), Futuramed Publishers. 1992;  Munich, Germany.

Date: 1992

Title: Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma.

Authors: Burzynski, S.R, Kubove, E., Burzynski, B.

Published By: Recent Advances in Chemotherapy.  Adam Dieter.  (Ed), Futuramed Publishers.  1992;  Munich, Germany.

Date: 1991

Title: Antineoplaston A5:  A growth inhibitor for cancerous cells and growth stimulator for normal cells.

Authors: Lee, S.S., Burzynski, S.R.

Published By: Internat J Exptl Clin Chemother. 1991; 4: 63-65.

Date: 1990

Title: Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1.

Authors: Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R.

Published By: Internat J Tissue Reactions. 1990; 12 (suppl): 43-50.

Date: 1990

Title: Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5.

Authors: Liau, M.C., Lee, S.S., Burzynski, S.R.

Published By: Internat J Tissue Reactions. 1990; 12 (suppl): 27-36.

Date: 1990

Title: Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5.

Authors: Lee, S.S., Burzynski, S.R.

Published By: Internat J Exptl Clin Chemother. 1990; 3: 125-128.

Date: 1990

Title: Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5.

Authors: Lee, S.S., Burzynski, S.R.

Published By: Internat J Tissue Reactions. 1990; 12 (suppl): 37-42.

Date: 1990

Title: Riboflavin as a minor active anticancer component of antineoplaston A2 and A5.

Authors: Liau, M.C., Ashraf, A.Q., Lee, S.S., Hendry, L.B., Burzynski, S.R.

Published By: Internat J Tissue Reactions. 1990; 12: 19-26.

Date: 1990

Title: Separation of active anticancer components of antineoplaston A2, A3, and A5.

Authors: Liau, M.C., Lee, S.S., Burzynski, S.R.

Published By: Internat J Tissue Reactions. 1990; 12 (suppl): 1-17.

Date: 1990

Title: Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1.

Authors: Burzynski, S.R., Kubove, E., Burzynski, B.

Published By: Drugs Exptl Clin Res. 1990; 16: 361-369.

Date: 1989

Title: Isolation, purification and synthesis of antineoplastons.

Authors: Burzynski, S.R.

Published By: Internat J Exptl Clin Chemother. 1989;  2: 63-69.

Date: 1989

Title: Hypomethylation of nucleic acids:  A key to the induction of terminal differentiation.

Authors: Liau, M.C., Lee, S.S., Burzynski, S.R.

Published By: Internat J Exptl Clin Chemother. 1989; 2: 187-199.

Date: 1988

Title: Modeling studies suggest the modified dipeptide analog phenylacetylamino-2, 6-piperidinedione may interact with DNA.

Authors: Hendry, L.B., Muldoon, T.G., Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988; 2:  11-13.

Date: 1988

Title: Antineoplastons: Basic research and clinical applications.

Authors: Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988; 2: 1-9.

Date: 1988

Title: Isolation, purification and synthesis of antineoplastons.

Authors: Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988; 6: 1-7.

Date: 1988

Title: Differentiation inducing components of antineoplaston A5.

Authors: Liau, M.C., Lee, S.S, Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988; 6: 9-25.

Date: 1988

Title: Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2.

Authors: Lee, S.S., Burzynski, S.R.

Published By: Adv Exptl  Clin Chemother. 1988; 6: 27-31.

Date: 1988

Title: Treatment of bladder cancer with antineoplaston formulations.

Authors: Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988. 2: 37-46.

Date: 1988

Title: Phase I clinical studies of oral formulation of antineoplaston AS2-1.

Authors: Burzynski, S.R., Kubove, E., Burzynski, B.

Published By: Adv Exptl Clin Chemother. 1988; 2: 29-36.

Date: 1988

Title: Treatment of malignant brain tumors with antineoplastons.

Authors: Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988; 6: 45-56.

Date: 1988

Title: Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats.

Authors: Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988;  6:  33-39.

Date: 1988

Title: Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients.

Authors: Ashraf, A.Q., Burzynski, S.R.

Published By: Adv Exptl Clin Chemother. 1988; 2: 19-28.

Date: 1987

Title: Tissue culture and animal toxicity studies of antineoplaston A5.

Authors: Lee, S.S., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 31-35.

Date: 1987

Title: Chemoprevention by antineoplaston A10 of benzo (a) pyrene-induced pulmonary neoplasia.

Authors: Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 51-55.

Date: 1987

Title: Chemosurveillance: A novel concept of the natural defense mechanism against cancer.

Authors: Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 71-76.

Date: 1987

Title: In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3.

Authors: Lee, S.S., Mohabbat, M.O., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 13-16.

Date: 1987

Title: N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents.

Authors: Khalid, M., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 57-60.

Date: 1987

Title: Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA.

Authors: Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 77-81.

Date: 1987

Title: Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up.

Authors: Burzynski, S.R., Kubove, E.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 1-12.

Date: 1987

Title: Phase I clinical studies of antineoplaston A3 injections.

Authors: Burzynski, S.R., Kubove, E.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 17-29.

Date: 1987

Title: Phase I clinical studies of antineoplaston A5 injections.

Authors: Burzynski, S.R., Kubove, E., Burzynski, B.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 37-43.

Date: 1987

Title: Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy.

Authors: Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 61-70.

Date: 1987

Title: Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats.

Authors: Ashraf, A.Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1987; 13 (suppl 1): 45-50.

Date: 1986

Title: Chronic animal toxicity studies of antineoplaston A2.

Authors: Burzynski, S.R., Mohabbat, M.O.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 73-75.

Date: 1986

Title: Preclinical studies on antineoplaston A10 injections.

Authors: Ashraf, A.Q., Liau, M.C., Mohabbat, M.O., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 37-45.

Date: 1986

Title: Preclinical studies on antineoplaston AS2-1 and antineoplaston AS2-5.

Authors: Burzynski, S.R., Mohabbat, M.O., Lee, S.S.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 11-16.

Date: 1986

Title: Antineoplaston A3.

Authors: Burzynski, S.R.

Published By: Drugs of the Future 1986; 11: 551-552.

Date: 1986

Title: Antineoplastons: History of the research (I)

Authors: Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 1-9.

Date: 1986

Title: Antineoplaston AS2-5.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report. 1986; 8: 319.

Date: 1986

Title: Antineoplaston AS2-1.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report. 1986; 8: 320.

Date: 1986

Title: Antineoplaston AS2-5.

Authors: Burzynski, S.R., Khalid, M.

Published By: Drugs of the Future  1986; 11: 364-365.

Date: 1986

Title: Antineoplaston A10 injections.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report. 1986; 8: 597.

Date: 1986

Title: Antineoplaston A3.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report. 1986; 8: 412.

Date: 1986

Title: Antineoplaston A2.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report.  1986; 8: 504.

Date: 1986

Title: Antineoplaston AS2-1.

Authors: Burzynski, S.R., Khalid, M.

Published By: Drugs of the Future 1986; 11: 361-363.

Date: 1986

Title: Antineoplaston A2.

Authors: Burzynski, S.R.

Published By: Drugs of the Future 1986; 11: 549-550.

Date: 1986

Title: Antineoplaston A5.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report. 1986; 8: 869.

Date: 1986

Title: Antineoplaston A5.

Authors: Burzynski, S.R.

Published By: Drugs of the Future 1986; 11: 824-825.

Date: 1986

Title: Synthetic antineoplastons and analogs.

Authors: Burzynski, S.R.

Published By: Drugs of the Future 1986; 11:  679-688.

Date: 1986

Title: Altered methylation complex isoenzymes as selective targets for cancer chemotherapy.

Authors: Liau, M.C., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 77-86.

Date: 1986

Title: 3-phenylacetylamino-2,6-piperidinedione, a naturally occurring peptide analogue with apparent antineoplastic activity, may bind to DNA.

Authors: Lehner, A.F., Burzynski, S.R., Hendry, L.B.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 57-72.

Date: 1986

Title: Toxicology studies on antineoplaston A10 injections in cancer patients.

Authors: Burzynski, S.R., Kubove, E.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 47-55.

Date: 1986

Title: Toxicology studies of antineoplaston AS2-5 injections in cancer patients.

Authors: Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 17-24.

Date: 1986

Title: Toxicology studies on antineoplaston AS2-1 injections in cancer patients.

Authors: Burzynski, S.R., Burzynski, B., Mohabbat, M.O.

Published By: Drugs Exptl Clin Res. 1986; 12 (suppl 1): 25-35.

Date: 1985

Title: Tissue culture and acute animal toxicity studies of antineoplaston A2.

Authors: Lee, S.S., Mohabbat, M.O., Burzynski, S.R.

Published By: Future Trends in Chemotherapy 1985; 6: 481-484.

Date: 1985

Title: Antineoplaston A10.

Authors: Burzynski, S.R., Hai, TT.

Published By: Drugs of the Future 1985; 10: 103-105.

Date: 1985

Title: Phase I clinical studies of antineoplaston AS2-5 injections.

Authors: Burzynski, S.R.

Published By: Recent Advances in Chemotherapy. Ishigami J. (Ed), University of Tokyo Press. Proceeding of the 14th International Congress of Chemotherapy, Kyoto, 1985, 586-7.

Date: 1985

Title: Toxicology studies on oral formulation of antineoplaston A10 in cancer patients.

Authors: Burzynski, S.R., Mohabbat, M.O., Burzynski, B.

Published By: Future Trends in Chemotherapy 1985;  6: 485-493.

Date: 1984

Title: Animal toxicology studies on oral formulation of antineoplaston A10.

Authors: Burzynski, S.R., Mohabbat, M.O., Burzynski, B.

Published By: Drugs Exptl Clin Res. 1984; 10: 113-118.

Date: 1984

Title: Tissue culture and animal toxicity studies of antineoplaston A2.

Authors: Lee, S.S., Mohabbat, M.O., Burzynski, S.R.

Published By: Drugs Exptl Clin Res. 1984; 10: 607-610.

Date: 1984

Title: Antineoplaston A10.

Authors: Burzynski, S.R.

Published By: Annual Drug Data Report. 1984; 6: 124.

Date: 1984

Title: Human toxicology studies on oral formulation of antineoplaston A10.

Authors: Burzynski, S.R., Mohabbat, M.O., Burzynski, B.

Published By: Drugs Exptl Clin Res. 1984; 10: 891-909.

Date: 1984

Title: Toxicology studies on oral formulation of antineoplaston A10 in cancer patients.

Authors: Burzynski, S.R., Mohabbat, M.O., Burzynski, B.

Published By: Drugs Exptl Clin Res. 1984; 10: 611-619.

Date: 1979

Title: Polypeptides that inhibit human breast cancer cell division.

Authors: Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F.

Published By: Cancer Biochem Biophys. 1979; 3: 93-96.

Date: 1978

Title: Antyneoplastony.

Authors: Burzynski, S.R.

Published By: Przeglad Lekarski. 1978; 6: 583-586.

Date: 1977

Title: Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells.

Authors: Gross, S., Galicka, N., Grabarczyk, M., Giannini, M., Burzynski, S.R., Stolzmann, Z.

Published By: Clin Chem. 1977; 23: 148-149.

Date: 1977

Title: Antineoplaston A in cancer therapy (I).

Authors: Burzynski, S.R., Stolzmann, Z., Szopa, B., Stolzmann, E., Kaltenberg, O.P.

Published By: Physiol Chem Phys. 1977; 9: 485-500.

Date: 1976

Title: Antineoplastons: Biochemical defense against cancer.

Authors: Burzynski, S.R.

Published By: Physiol Chem Phys.  1976; 8: 275-279.

Date: 1976

Title: Urinary peptides in muscular dystrophy.

Authors: Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A.

Published By: Physiol Chem Phys. 1976; 8: 161-166.

Date: 1976

Title: Sequential analysis in subnanomolar amounts of peptides;  Determination of the structure of a habituation-induced brain peptide (ameletin).

Authors: Burzynski, S.R.

Published By: Anal Biochem. 1976; 70: 359-365.

Date: 1976

Title: Biologically active peptides in human urine:  III.  Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells.

Authors: Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H.

Published By: Physiol Chem Phys. 1976; 8: 13-22.

Date: 1976

Title: Inhibition of the Growth of HeLa Cells by the Peptide Isolated from Normal Human Urine.

Authors: Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z.

Published By: Fed Proc. 1976; 35: 623.

Date: 1975

Title: Quantitative analysis of amino acids and peptides in the femtomolar range.

Authors: Burzynski, S.R.

Published By: Anal Biochem. 1975; 65: 93-99.

Date: 1975

Title: Brain Peptides Associated with Habituation to a Sound Stimulus.

Authors: Burzynski, S.R., Ungar, G.

Published By: Neuroscience Abstracts. 1975; 1: 329.

Date: 1975

Title: Learning-induced Brain Peptides.

Authors: Ungar, G., Burzynski, S.R., Tate, D.L.

Published By: Peptides: Chemistry, structure and biology. Walter, R., Meienhofer, J. (Ed),  Ann Arbor Science; 1975; Ann Arbor, Michigan, USA.

Date: 1974

Title: Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart.

Authors: Burzynski, S.R., Ungar, A.L., Lubanski, E.

Published By: Physiol Chem Phys. 1974; 6: 457-468.

Date: 1974

Title: Effect of Urinary Peptides on Smooth Muscle and Heart.

Authors: Burzynski, S.R., Ungar, A.L., Lubanski, E.

Published By: Fed Proc. 1974; 33: 547.

Date: 1973

Title: Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides.

Authors: Burzynski, S.R.

Published By: Physiol Chem Phys. 1973; 5: 437-447.

Date: 1973

Title: Effect of Urinary  Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells.

Authors: Burzynski, S.R., Georgiades, J.

Published By: Fed Proc. 1973; 32: 766.

Date: 1973

Title: Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain.

Authors: Ungar, G., Burzynski, S.R.

Published By: Fed Proc. 1973; 32: 367.

Date: 1970

Title: A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum.

Authors: Burzynski, S.R., Czerniak, Z.

Published By: Chem Anal.  1970; 15: 223-225.

Date: 1970

Title: Free amino acids in serum of obese children.

Authors: Szajner-Milart, J., Burzynski, S.R., Paczos-Chadyma, E., Czerniak, Z.

Published By: Endokr Pol. 1970; 21: 611-617.

Date: 1969

Title: Quantitative determinations of carbohydrates and their statistical analysis, I.  Results obtained in various conditions using paper and thin-layer chromatography.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Chem Anal. 1969; 13: 1221-1228.

Date: 1969

Title: Investigations on unknown ninhydrin-reacting substances in human blood serum I.  Attempts at identification of three such substances.

Authors: Burzynski, S.R.

Published By: Experientia. 1969; 25: 490-491.

Date: 1969

Title: Bound amino acids in serum of patients with chronic renal insufficiency.

Authors: Burzynski, S.R.

Published By: Clin Chim Acta. 1969; 25: 231-237.

Date: 1969

Title: Free amino acids in serum of patients with chronic renal insufficiency.

Authors: Czerniak, Z., Burzynski, S.

Published By: Clin Chim Acta. 1969; 24: 367-372.

Date: 1969

Title: A simple method for free and bound amino acid separation.

Authors: Burzynski, S.R., Czerniak, Z.

Published By: Folia Soc Sci Lub.  1969/70;  Sec. A-D 9/10 (suppl):  143-144.

Date: 1969

Title: Quantitative determination of amino acids using photometry of negative printed chromatograms.  Modification of the method and its application for amino acid analysis in blood serum.

Authors: Burzynski, S.R., Czerniak, Z.

Published By: Chem Anal. 1969; 14:  667-671.

Date: 1969

Title: Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents.

Authors: Czerniak, Z., Burzynski, S.

Published By: Chem Anal. 1969; 14:  673-676.

Date: 1968

Title: Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Pol Arch Med Wewn. 1968; 40: 223-228.

Date: 1968

Title: Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Pol Arch Med Wewn. 1968;  41: 361-368.

Date: 1968

Title: Quantitative determinations of carbohydrates and their statistical analysis, II.  Analysis of variance for four-crossed classification and Tukey confidence intervals.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Chem Anal. 1968; 13: 1229-1238.

Date: 1968

Title: Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency.

Authors: Burzynski, S.R.

Published By: Doctoral dissertation. Lublin, Poland, 1968.

Date: 1966

Title: Quantitative determination of amino acids using photometry of negative printed chromatograms.

Authors: Krzeczkowska, I., Burzynski, S., Czerniak, Z.

Published By: Ann Univ MC Sklodowska 1966; 21: 125-134.

Date: 1966

Title: The application of the negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Ann Univ MC Sklodowska 1966; 21: 313-322.

Date: 1965

Title: Investigations on the possibility of the determination of mushroom species on the basis of the composition of their amino acids.

Authors: Krzeczkowska, I., Burzynski, S., Czerniak, Z.

Published By: Ann Univ MC Sklodowska 1965; 20: 221-229.

Date: 1965

Title: Free and bound amino acids of some edible mushrooms.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Ann Univ MC Sklodowska 1965; 20: 303-312.

Date: 1964

Title: Free amino acids of some edible mushrooms.

Authors: Krzeczkowska, I., Burzynski, S., Czerniak, Z.

Published By: Ann Univ MC Sklodowska 1964; 19: 321-328.

Date: 1964

Title: Bound amino acids of some edible mushrooms.

Authors: Krzeczkowska, I., Czerniak, Z., Burzynski, S.

Published By: Ann Univ MC Sklodowska 1964; 19: 329-336.
SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES: Burzynski, S.R. Current innovations in cancer treatment. War on cancer, Texas chapter. Presented at The Truth About Cancer LIVE; October 5, 2017 – October 7, 2017; Orlando, FL.

Burzynski, S.R. Precision therapy of glioblastoma. Presented at BIT’s 8^th Annual World Congress of NeuroTalk-2017; May 22, 2017 – May 24, 2017; Barcelona, Spain.

Burzynski, S.R., Janicki, T., Burzynski, G. Treatment of children with primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in phase II studies with antineoplastons A10 and AS2-1. Presented at the 18^th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 12, 2016 – June 15, 2016; Liverpool, U.K.

Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004. Presented at the 16^th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 28, 2014 – July 2, 2014; Singapore.

Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017. Presented at the 16^th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 28, 2014 – July 2, 2014; Singapore.

Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020. Presented at the 16^th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 28, 2014 – July 2, 2014; Singapore.

Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. Presented at the 4^th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.

Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. Presented at the 4^th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.

Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). Presented at the 4^th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.

Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. Presented at the 4^th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California, USA.

Burzynski, S.R. Molecular profiling in oncology practice: The results of treatment in a group of 1,633 patients.” Presented at BIT’s 4^th Annual World Cancer Congress – 2011; May 22-25, 2011; Dalian, China.

Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas. Presented at the 15^th Annual Scientific Meeting of the Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada.

Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons. Presented at the 15^th Annual Scientific Meeting of the Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada.

Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Presented at the 14^th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.

Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Presented at the 14^th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Protocol BC-BT-11. Presented at the 3^rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6^th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Presented at the 3^rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6^th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K. Antineoplastons inhibit MCM complex in glioblastoma cells. Presented at the 3^rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6^th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

Burzynski, S.R. New research on molecular mechanisms and prevention of Alzheimer’s disease. Presented at the 17^th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; April 21-April 25, 2009; Orlando, Florida.

Burzynski, S. Life extension through application of chromatin remodeling agents. Presented at the 7^th Anti-Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco.

Marquis, A., Kubove, E., Walczak, M., Burzynski, S. Hepatocellular carcinoma, recurrent after standard therapy, successfully treated with a combination of targeted therapies. Presented at the 20^th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

Weaver, R., De Leon, L., Burzynski, S. A complete response in a patient with inoperable adenocarcinoma of the head of the pancreas treated with a combination of gene-targeted therapies. Presented at the 20^th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

Burzynski, S.R. The Coming Pandemic of Liver Cancer. In Search of Genomic Solutions. Presented at the 16^th Annual World Congress of A4M, Winter 2008 Session; December 12-December 15, 2008; Las Vegas, Nevada.

Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Presented at the 13^th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells. Presented at the 13^th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

Burzynski, S.R., Patil, S., Ilkowska-Musial, E., Chittur, S., Gupta, V., Sarangi, R. Pathway analysis of the effect of chromatin remodeling agent phenylbutyrate on the brains of honeybees. Presented at Neuroscience 2008; November 15-November 19, 2008; Washington D.C.

Burzynski, S.R. Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials. Presented at the Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7-November 9, 2008; Dubai.

Burzynski, S.R. Antineoplastons and Targeted Gene Therapy. Presented at ACAM Scientific Conference; October 15-October 19, 2008; Las Vegas, Nevada.

Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.

Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.

Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11-September 14, 2008; Düsseldorf, Germany.

Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Presented at the 13^th International Symposium on Pediatric Neuro-Oncology; June 29-July 2, 2008; Chicago, Illinois.

Burzynski, S.R. Genome, Epigenome and Aging. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.

Burzynski, S.R. Personalized Cancer Treatment in Genomics Era. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.

Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animals and human clinical trials. Presented at the 16^th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida.

Burzynski, S.R. Antineoplaston peptides in treating cancer. Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.

Burzynski, S.R. Anti-Aging peptides—a new frontier in healing. Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.

Burzynski, S.R. Genomic approach to cancer treatment. Presented at the 15^th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada.

Burzynski, S.R. Genomics in Cancer Treatment. Presented at the 1^st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.

Burzynski, S.R. Epigenomic Approach to Anti-Aging. Presented at the 1^st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.

Burzynski, S.R., Weaver, R.A., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent, diffuse, intrinsic brainstem anaplastic astrocytoma. Presented at the Society for Neuro-Oncology 12^th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Presented at the Society for Neuro-Oncology 12^th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

Burzynski, S.R., Tempczyk-Russell, A., Ilkowska-Musial, E. Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory. Presented at Neuroscience 2007, the Society’s Annual Meeting; November 3-7, 2007; Sand Diego, California.

Burzynski, S.R. Epigenomic approach to anti-aging. Presented at: 4^th Congresso Internacional de Antienvelhecimento; October 26-27, 2007; Sao Paulo, Brazil.

Burzynski, S.R. Nutrition and ageing : Gene silencing or gene activation. Presented at: 10^th European Nutrition Conference; July 10-13, 2007; Paris, France.

Burzynski, S.R. La solution génétique contre le vieillissement. Presented at: Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo.

Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. Presented at: 14^th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada.

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.J., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with Antineoplastons (ANP) A10 and AS2-1. Presented at the Society for Neuro-Oncology’s 11^th Annual Meeting; November 16-19, 2006; Orlando, Florida.

Burzynski, S.R., Christensen, R., Ilkowska-Musial, E. Memory processing proteins have common amino acid sequences with Scotophobin. Presented at: Neuroscience 2006, the Society’s 36^th annual meeting; October 14-18, 2006; Atlanta, Georgia.

Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B., Jurida, G.F. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brainstem gliomas. Presented at: The European Association for Neuro Oncology: 7^th Congress Vienna Hofburg Congress Center; September 14-17, 2006; Vienna, Austria.

Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons. Presented at: 14^th Annual International Congress on Anti-Aging Medicine; July 14-16, 2006; Chicago, Illinois.

Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 1^st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (III) Aminocare Products and Aging of the Brain. Presented at: 1^st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (II) Aminocare Products and Skin Aging. Presented at: 1^st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (I) Theory and Age-Management with Aminocare Products. Presented at: 1^st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan

Burzynski, S.R. Gene Silencing Theory of Aging. Presented at: 1^st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Presented at: 12^th International Symposium on Pediatric Neuro-Oncology; June 6-9, 2006; Nara, Japan.

Burzynski, S.R. Chronobiology of Aging. Presented at: International Danube Symposium for Neurological Sciences and Continuing Education; May 10-13, 2006; Kazimierz Dolny, Poland.

Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 14^th International Congress on Anti-Aging Medicine; April 7-9, 2006; Orlando, Florida.

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Jurida, G.F. Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas. Presented at the 17th International Congress on Anti-Cancer Treatment; January 30-February 2, 2006; Paris, France.

Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. Presented at: XIII International Congres on Anti-Aging Medicine; December 8-12, 2005; Las Vegas, Nevada.

Burzynski, S.R. Master Clock of Life (I) "Junk DNA" and Promotors Region as Major Components of the Clock. Presented at: XIII International Congres of Anti-Aging Medicine; August 19-21, 2005; Chicago, Illinois.

Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.

Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 (ANP) of high grade, recurrent and progressive brain stem glioma. Presented at the 16th International Congress on Anti-Cancer Treatment; February 1-4, 2005; Paris, France.

Burzynski, S.R. Antineoplastons. Presented at: The Cleveland Clinic Neuro-Oncology 2005: Current Concepts; January 29-31, 2005; Lake Buena Vista, FL, USA.

Burzynski, S.R., Jacquet, A., Moore, N., Musial, L. Gene silencing theory of aging: the clinical trial supporting the theory. Presented at: American Academy of Anti-Aging Medicine (A4M) Conference on Anti-Aging Medicine, December 2-5, 2004; Las Vegas, USA.

Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.

Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.

Burzynski, S.R., Janicki, T., Weaver, R., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Clinical application of body epigenetic system. Multi-targeted therapy for primary brain tumors. Presented at World Conference on Magic Bullets Celebrating Paul Ehrlich's 150th Birthday; September, 2004; Nurnberg, Germany.

Burzynski, S.R. The new generation of food supplements effecting gene expression. Presented at 2nd Congress Food, Nutrition and Health in Poland Integrated with European Union; June 23-26, 2004; Warsaw, Poland.

Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Szymkowski, B., Jurida G., Khan, M., Dolgopolov, V. Treatment of Primitive Neuroectodermal Tumors (PNET) with Antineoplastons A10 and AS2-1 (ANP). Preliminary Results of Phase II Studies. Presented at 11th International Symposium on Pediatric Nuero-Oncology; June 13-16, 2004; Boston, MA.

Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Jurida G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II Studies of Antineoplastons A10 and AS2-1 (ANP) in Children with Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System. A Preliminary Report. Presented at 11th International Symposium on Pediatric Neuro-Oncology; June 13-16, 2004; Boston, MA.

Burzynski, S.R., Lewy, R.I., Axler, M., Janicki, T.J. Treatment of Malignant Mesothelioma (MM) with Sodium Phenylbutyrate. Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.

Waldbillig, R.J., Mrowczynski, E., Burzynski, S.R. Phenylacetic acid (PN) and Phenylacetylglutamine (PG): Mechanism of Uptake and changes in Epigenetic-Mechanisms Regulating Gene Expression. Presented at the 2nd Annual American Association for Cancer Research (AACR) International Conference; October 26-30, 2003, Phoenix, AZ.

Burzynski, S.R. Interaction of antineoplastons with genome in cancer and aging. Presented at: Annual Meeting of International Academy of Oral Medicine and Toxicology; September 12-13, 2003, New Orleans, Louisiana.

Burzynski, S.R. Antineoplastons in: Cancer Treatment and Age Management Therapy. Presented at American Collage for Advancement in Medicine (ACAM); May 16, 2003, Washington, DC.

Burzynski, S.R. The State of Antineoplaston Research - Spring of 2003. Presented at the 5th Annual Comprehensive Cancer Care Conference; April 11, 2003, Washington, DC.

Waldbillig, R.J., Burzynski, S.R. The application of chromatography to the pharmacokinetic study of Antineoplastons A10 and AS2-1. Presented at the 3rd International Symposium of Chromatography and Natural Products; June 12-15, 2002, Lublin, Poland.

Burzynski, S.R. Antineoplastons. Presented at 'Health-Trends 2000', The 2nd International Conference; August 27-29, 1999, Copenhagen, Denmark.

Burzynski, S.R. Phase II Trial of Antineoplaston A10 and AS2-1 in Brain Stem Glioma. Presented at International Conference on Integrative Medicine; May 1, 1999, Seattle, Washington, USA.

Czerwinski, A., Klimczak, M.W., Burzynski, S.R. Enancjoselektywna analiza skladnikow Antyneoplastonu A10 metoda HPLC. Presented at the XVII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego, September 1998, Krakow, Poland.

Burzynski, S.R. Gene Therapy with Antineoplastons. Presented at Comprehensive Cancer Care; June, 1998, Washington, D.C., USA.

Burzynski, S.R. Antineoplastons in the Treatment of Malignant Brain Tumors. Presented at 5^th International Conference of Anti-Aging Medicine and Biomedical Technology; December, 1997, Las Vegas, Nevada, USA.

Burzynski, S.R. New Concepts in Innovative Cancer Therapies. Presented at 4th Annual Conference on Anti-Aging Medicine and Biomedical Technology; Dec., 1996, Las Vegas, Nevada, USA.

Burzynski, S.R. Antineoplastons Today. Presented at the First International Congress On Alternative & Complementary Medicine; May, 1995; Washington, DC, USA.

Soltysiak-Pawluczuk, D., Burzynski, S.R. Uptake Characteristics of Antineoplaston AS2-1 by Human Hepatoma Cells. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

Lee, S.S., Burzynski, S.R. Synergistic Inhibitory Effect of Antineoplaston A5 and Thymidine on the Growth of Human Cancer Cell Lines. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

Liau, M.C., Liau, C.P., Burzynski, S.R. Helper Inducers of Terminal Differentiation. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

Burzynski, S.R., Szymkowski, B., Kubove, E. Phase II Clinical Trials of Antineoplaston AS2-1 in Asymptomatic HIV Infection. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

Burzynski, S.R., Kubove, E., Szymkowski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in High Grade Glioma. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

Kleinrok, Z., Burzynski, S.R., Juszkiewicz, M., Chodkowska, A., Feldo, M. The Influence of Antineoplaston A5 on the Central Dopaminergic Structures. Presented at: 11th Congress of the Polish Pharmacological Society; September, 1992; Gdansk, Poland.

Burzynski, S.R., Kubove, E., Szymkowski, B., Burzynski, B. Phase II Clinical Trials of Novel Differentiation Inducer - Antineoplaston AS2-1 in AIDS and Asymptomatic HIV Infection. VIII International Conference on AIDS/III STD World Congress; July, 1992; Amsterdam, The Netherlands.

Burzynski, S.R. Differentiation Inducers-Possible Agents for Cancer Therapy in Pregnancy. Presented at the World Congress of Prenatal and Perinatal Psychology and Medicine; May, 1992; Krakow, Poland.

Burzynski, S.R., Kubove, E., Burzynski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in Astrocytoma. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of Drug-Induced DNA Hypermethylation by Antineoplastons. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

Liau, M.C., Lee, S.S., Liau, C.P., Burzynski, S.R. Efficient Methylation when Locked in Place Becomes a Major Problem of Cancer. Presented at the 82nd Annual Meeting of the American Association for Cancer Research, May, 1991, Houston, Texas, USA.

Burzynski, S.R. Antineoplastons. Presented at: The World Research Foundation Congress, October 7, 1990, Los Angeles, CA, USA.

Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston AS2-1 Following Oral Administration in Rats. Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.

Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of Hormonally Refractory Cancer of the Prostate with Antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.

Liau, M.C., Lee, S.S., Burzynski, S.R. Abnormal Methylation Enzymes as Selective Targets of Cancer Therapy. Presented at the 42nd Annual Symposium on Fundamental Cancer Research, M.D. Anderson Hospital and Tumor Institute; October, 1989; Houston, Texas, USA.

Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of Nucleic Acids: A Key to the Induction of Terminal Differentiation. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

Burzynski, S.R. Antineoplastons - New Way for Cancer Chemotherapy. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

Liau, M.C., Lee, S.S., Burzynski, S.R. Role of Methylation Enzymes in Directing Phenotypic Changes. Presented at the 41st Annual Symposium on Fundamental Cancer Research. M.D. Anderson Hospital and Tumor Institute; October, 1988; Houston, Texas, USA.

Liau, M.C., Khalid, M., Burzynski, S.R. Differentiation Inducing Factors of Antineoplaston A5. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

Khalid, M., Burzynski, S.R. Phenylacetylglutamine Derivatives as Novel Chemotherapeutic Agents. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

Lee, S. S., Burzynski, S.R. Terminal Differentiation of HL-60 Human Promyelocytic Leukemia Cells Induced by Antineoplaston A2. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Analysis of Antineoplaston A10 Injections Following Intravenous Administration in Rats. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

Burzynski, S.R. Treatment of Malignant Brain Tumors with Antineoplastons. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of Tumor Methylation Complex Isozymes as a Decisive Factor in the Induction of Differentiation by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

Lee, S.S., Burzynski, S.R. Induction of Differentiation of HL-60 Human Promyelocytic Leukemic Cells by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective Effect of Antineoplaston A10 in Hepatocarcinogenesis Induced by Aflatoxin B 1. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston A3. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

Liau, M.C., Ashraf, A.Q., Burzynski, S.R. Active Anticancer Components of Antineoplaston Formulations. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

Ashraf, A.Q., Burzynski, S.R. Comparative Study of Antineoplaston A10 Levels in Plasma of Healthy People and Cancer Patients. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

Burzynski, S.R. Treatment of Bladder Cancer with Antineoplaston Formulations. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

Burzynski, S.R. Antineoplastons: Basic Research and Clinical Applications. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

Burzynski, S.R. Modeling Studies Suggest the Modified Dipeptide Analog Phenylacetylamino-2, 6-piperidinedione May Interact with DNA. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston AS2-1. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

Lee, S.S., Burzynski, S.R. A Unique Pattern of Growth Inhibition by Antineoplaston A5 on a T-Leukemia Cell Line. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.

Liau, M.C., Kampalath, B.N., Szopa, M., Burzynski, B., Burzynski, S.R. Chemo-surveillance: A Novel Concept on the Natural Defense Mechanism Against Cancer. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.

Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by Antineoplaston A10 on Benzo (1) pyrene Induced Pulmonary Neoplasia. Presented at the 5th Mediterranean Congress of Chemotherapy; October, 1986; Cairo, Egypt.

Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A2 Injections. Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.

Hendry, L.B., Lehner, A.F., Muldoon, T.G., Copland, J.A., Mahesh, V.B., Mills, T.M., Burzynski, S.R. Investigations of the Mode of Action of Antineoplaston A10: Evidence for Binding to DNA. Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.

Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Antineoplaston A5 Injections. Presented at the III World Conference on Clinical Pharmacology and Therapeutics; July, 1986; Stockholm, Sweden.

Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A3 Injections. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as Novel Cancer Chemotherapeutic Agents. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In Vitro Cancer Growth Inhibition and Acute Animal Toxicity Studies of Antineoplaston A3. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

Lehner, A.F., Copland, J.A., Muldoon, T.G., Burzynski, S.R., Hendry, L.B. In Vitro Studies of the Stereospecificity of Antineoplaston A10 Interaction with Double-stranded DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

Ashraf, A.Q., Kampalath, B.N., Liau, M.C., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston A10 Following Oral Administration in Rats. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical Modeling Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston Al 0 Injections. Presented at the 2nd Biennial Conference of Indian Society of Oncology; February, 1986; Bombay, India.

Burzynski, S.R., Lehner, A.F., Hendry, L.B. Putative Mechanism of Action of a Novel Peptide Analog with Apparent Antineoplastic Activity: Stereospecific interaction with DNA. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.

Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative Assay of Plasma and Urinary Peptides as Aid for Evaluation of Cancer Patients Undergoing Antineoplaston Therapy. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.

Hendry, L.B. Lehner, A.F., Burzynski, S.R. A Novel Naturally-occurring Peptide Analog with Apparent Antineoplastic Activity May Interact with DNA. Presented at the International Symposium, Cancer: Perspective for Control; August, 1985; Beijing, China.

Hendry, L.B., Lehner, A.F., Burzynski, S.R. Spectroscopic Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 12th Symposium of the International Association for Comparative Research on Leukemia and Related Disease; July, 1985; Hamburg, Germany.

Burzynski, S.R. Phase I Clinical Studies of Antineoplaston AS2-5 Injections. Presented at the 14th International Congress of Chemotherapy; June, 1985; Kyoto, Japan.

Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Phase I Clinical Studies of Antineoplaston AS2-1 Injection. Presented at the 3rd European Conference on Clinical Oncology and Cancer Nursing; June, 1985; Stockholm, Sweden.

Liau, M.C., Burzynski, S.R. Alteration of Methylation Complex of Isoenzymes Critical to Malignant Evolution. Presented at the 12th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, October, 1984; Houston, USA.

Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology Studies of Oral Formulation of Antineoplaston A10 in Cancer Patients. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.

Lee, S. S., Mohabbat, M.O., Burzynski, S.R. Tissue Culture and Animal Toxicity Studies of Antineoplaston A2. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.

Burzynski, S.R., Hendry, L.B., Mohabbat, M.O., Liau, M.C., Khalid, M., Burzynski, B. Purification, Structure Determination, Synthesis and Animal Toxicity Studies of Antineoplaston A10; PS 12.4.11-4. Presented at the 13th International Congress on Chemotherapy, TOM 17; August, 1983; Vienna, Austria.

Burzynski, S.R. Recent Advances in Ultramicroanalysis of Biologically Active Peptides. Presented at the 30th Southwest Regional American Chemical Society meeting, 1974; Houston, Texas.

Ungar, G., Burzynski, S.R. Detection of a Behavior-inducing Peptide (Scotophobin) in Brain by Ultramicroanalytical Method. Fed Proc., 1972; 31: 398.

Burzynski, S.R., Czerniak, Z. The Photometry of Negative Printed Chromatograms and its Application for Amino Acid Analysis in Human Blood. Biuletyn VII Ogolnopolskiej Konferencji Studenckich Kol Naukowych Akademii Medycznych; 1966; Poznan, Poland.
PATENTS AND TRADEMARKS: Arab Emirates

Burzynski, S.R. Patent No: 386 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 3/20/2013)

Australia

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: 551109 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 8/18/1986)

Burzynski, S.R. Patent No: 638869 Pharmaceutical compositions for use in treating AIDS. (granted 11/1/1993)

Burzynski, S.R. Patent No: 642045 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 2/1/1994)

Burzynski, S.R. Patent No: 656484 Compositions and methods for treating autoimmune

diseases. (granted 5/18/1995)

Burzynski, S.R. Patent No: 683145 Methods for treating neurofibromatosis. (granted 2/19/1998)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 757114 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 5/22/2003)

Burzynski, S.R. Patent No: 759278 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 7/24/2003)

Burzynski, S.R. Patent No: 2002352843 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 8/2/2007)

Burzynski, S.R. Patent No.: 2018266375 Methods for the treatment of recurrent glioblastoma (RGBM). (granted 5/7/2018)

Austria

Burzynski, S.R. Patent No: 0069232 Patent No. National: E23113 Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Patent No. National: ATE135,217 Pharmaceutical

compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Patent No. National: E162,714 Compositions and methods for treating autoimmune diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Patent No. National: E183,390 Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Belgium

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Benelux

Trademark Patent No: 0663625 AMINOCARE (Trademark 9/1/2000)

Canada

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 1188218 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 6/4/1985)

Burzynski, S.R. Patent No: 1262866 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation. (granted 11/14/1989)

Burzynski, S.R. Patent No: 1262907 3-[N-Phenylacetylaminopiperidine]-2,6 Dion and Process of Synthesizing Same. (granted 11/14/1989)

Burzynski, S.R., Byra, A., Waldbilling, R.J. Patent No: 2254772 Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity. (granted 1/27/2004)

Burzynski, S.R. Patent No: 2345409 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 9/9/2008)

Burzynski, S.R. Patent No: 2336945 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 11/18/2008)

Burzynski, S.R. Patent No: 2447803 Synthesis of 4-phenylbutyric acid. (granted 4/7/2009)

Burzynski, S.R. Patent No: 2468133 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 2/22/2011)

China

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: ZL 99811314.X Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 3/2/2005)

Burzynski, S.R. Patent No: ZL02810264.9 Synthesis of 4-phenylbutyric acid. (granted

7/26/2006)

Trademark Patent No: Reg.No.: CDN-HY-07011055; (56); (57). China Domain Name

Registration Certificate. Internet Keyword: aminocare. Valid until: 5/23/2017

China Domain Name Registration Certificate. Internet Keyword: aminocare.cn. Valid until: 5/23/2012

China Domain Name Registration Certificate. Internet Keyword: aminocare.com.cn. Valid until: 5/23/2012 (Trade_Name 5/23/2007)

Burzynski, S.R. Patent No: ZL02823606.8 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 1/2/2008)

Burzynski, S.R. Patent No: ZL200410061600.5 A composition for treating neoplastic disease and the use thereof. (granted 7/9/2008)

Trademark Patent No: 4695730 Aminocare. (Trademark 10/21/2008)

Trademark Patent No: 10328784 Avavital in Class 5. (Trademark 2/21/2013)

Trademark Patent No: 10328785 Atengenal in Class 5. (Trademark 2/28/2013)

Trademark Patent No: 10328787 Cengenal in Class 5. (Trademark 2/28/2013)

Trademark Patent No: 10328788 Fengenal in Class 5 (Trademark 2/28/2013)

Denmark

Burzynski, S.R. Patent No: 162813 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 5/4/1992)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Eurasia

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Readiness to Grant )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 004179 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

Contracting States: AM - AZ - BY - KZ - KG - MD - RU. (granted 2/26/2004)

Burzynski, S.R. Patent No: 009516 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Contracting States: AM-AZ-BY-KG-KZ-MD-RU-TJ-TM. (granted 11/6/2007)

Burzynski, S.R. Patent No: 012908 Method for treatment of Von Hippel-Lindau (VHL)

disease with phenylacetyl-derivatives.

Contracting States: RU. (granted 2/26/2010)

Europe

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione.

Contracting States: AT-BE-CH-DE-FR-GB-IT-LI-LU-NL-SE (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.

Contracting States: AT-BE-CH-DE-FR-GB-IT-LI-LU-NL-SE (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease.

Contracting States: AT-BE-CH-DE-DK-ES-FR-GB-GR-IT-LI-LU-NL-SE (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS.

Contracting States: AT-BE-CH-DE-DK-ES-FR-GB-GR-IT-LI-LU-NL-SE (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases.

Contracting States: AT-BE-CH-DE-DK-ES-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE

(granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis.

Contracting States: AT-BE-CH-DE-DK-ES-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE

Extension: LT-SI (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections.

Contracting States: AT-BE-CH-DE-DK-ES-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE

(granted 1/19/2000)

Burzynski, S.R. Patent No: 1098643 Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of Neoplastic Disease.

Contracting States: AT-BE-CH-CY-DE-DK-ES-FI-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE Extension: LV (granted 1/7/2004)

Burzynski, S.R. Patent No: 1171110 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

Contracting States: AT-BE-CH-CY-DE-DK-ES-FI-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE Extension: LT-LV-RO-SE (granted 4/7/2004)

Burzynski, S.R. Patent No: 1206936 Phenylacetic Acid Compositions for Treating or

Preventing Hypercholesterolemia.

Contracting States: AT- BE-CH-CY-DE-DK-ES-FI-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE-TR Extension: LT-LV (granted 8/24/2005)

Burzynski, S.R., Byra, A., Waldbilling, R.J. Patent No: 0906088 Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

Contracting States: AT-BE-CH-DE-DK-ES-FI-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE (granted 11/23/2005)

Trademark Patent No: 004006425 Cengenal in Class 5 (Trademark 12/9/2005)

Trademark Patent No: 004006979 Atengenal in Class 5 (Trademark 12/9/2005)

Trademark Patent No: 004006102 Fengenal in Class 5 (Trademark 12/15/2005)

Trademark Patent No: 004006359 Bugenal in Class 5 (Trademark 12/15/2005)

Trademark Patent No: 004006375 Lubgen Farma in Class 39 (distribution of pharmaceutical preparation) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)

(Trademark 12/15/2005)

Trademark Patent No: 004006664 Astugenal in Class 5 (Trademark 12/15/2005)

Burzynski, S.R. Patent No: 1450781 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Contracting States: AT-BE-BG-CH-CY-CZ-DE-DK-EE-ES-FI-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE-SK-TR: Extension:LT-LV. (granted 6/21/2006)

Trademark Patent No: 004006334 Avavital in Class 5 (Trademark 3/18/2008)

Burzynski, S.R. Patent No: 1855665 Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.

Contracting States: AT-BE-BG-CH-CY-CZ-DE-DK-EE-ES-FI-FR-GB-GR-HU-IE-IS-IT-LI-LT-LU-LV-MC-NL-PL-PT-RO-SE-SI-SK-TR (granted 12/31/2008)

Burzynski, S.R., Musial, L. Patent No: 1404638 Synthesis of 4-phenylbutyric acid.

Contracting States: AT-BE-CH-CY-DE-DK-ES-FI-FR-GB-GR-IE-IT-LI-LU-MC-NL-PT-SE-TR (granted 7/27/2011)

Finland

Burzynski, S.R. Patent No: 92391 Methods for preparing 3-(N-phenylacetylamino-

piperidine)-2,6-dion. (granted 11/10/1994)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

France

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of Neoplastic Disease. (granted 1/7/2004)

Burzynski, S.R., Byra, A., Waldbilling, R.J. Patent No: 0906088 Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity. (granted 11/23/2005)

Germany

Burzynski, S.R. Patent No: 0069232 Patent No. National: P3273952.4 Pharmaceutical

composition comprising phenylacetylglutamine, a combination of this compound with

phenylacetic acid or 3-(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Patent No. National: 69114261.0 Pharmaceutical

compositions for use in treating Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Patent No. National: 69117923 Pharmaceutical

compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Patent No. National: 69316729.7 Compositions and

methods for treating autoimmune diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Patent No. National: 69511453.0 Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Patent No. National: 69327642.8 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Patent No. National: 69914084.6-08

Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of Neoplastic Disease. (granted 1/7/2004)

Burzynski, S.R. Patent No: 69916330T2 Patent No. National: 69916330T2 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 4/7/2004)

Burzynski, S.R. Patent No: 60112872T2 Patent No. National: 60112872T2 Phenylacetic Acid Compositions for Treating or Preventing Hypercholesterolemia. (granted 8/24/2005)

Burzynski, S.R., Byra, A., Waldbilling, R.J. Patent No: 0906088 Patent No. National:

DE69734713T2 Liposomal Antineoplastons Therapies with Markedly Improved

Antineoplastic Activity. (granted 11/23/2005)

Burzynski, S.R. Patent No: DE60212393T2 Patent No. National: DE60212393T2 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 7/5/2007)

Greece

Burzynski, S.R. Patent No: 0500901 Patent No. National: 3018437 Pharmaceutical

compositions for use in treating Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Patent No. National: 3019970 Pharmaceutical

compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Patent No. National: 980400879 Compositions and

methods for treating autoimmune diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Hong Kong

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 302/1989 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 4/13/1989)

Burzynski, S.R. Patent No: 1016408 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 5/19/2000)

Burzynski, S.R. Patent No: 1037142 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 11/9/2001)

Burzynski, S.R. Patent No: 1045253 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 8/13/2004)

Trademark Patent No: 300343377 Aminocare in Class 5 (Trademark 6/21/2005)

Burzynski, S.R. Patent No: 1048588 Phenylacetic Acid Compositions for Treating or Preventing Hypercholesterolemia. (granted 1/13/2006)

Burzynski, S.R. Patent No: 1065996 Synthesis of 4-phenylbutyric acid. (granted 12/8/2006)

Trademark Patent No: 302118276 Avavital in Class 5 (Trademark 4/20/2012)

Trademark Patent No: 302118285 Atengenal in Class 5 (Trademark 4/20/2012)

Trademark Patent No: 302118294 Astugenal in Class 5 (Trademark 4/20/2012)

Trademark Patent No: 302118302 Cengenal in Class 5 (Trademark 4/20/2012)

Trademark Patent No: 302118311 Fengenal in Class 5 (Trademark 4/20/2012)

Hungary

Burzynski, S.R., Musial, L. Patent No: 229996 New process for synthesis of 4-phenylbutyric acid. (granted 5/9/2015)

Burzynski, S.R. Patent No: 230986 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (Pending 8/28/2019)

India

Burzynski, S.R. Patent No: 212246 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 11/26/2007)

Burzynski, S.R. Patent No: 227008 A Phamaceutical Composition Comprising

Phenylacetulglutamine, Phenylacetylisoglutamine, and/or Phanylacetate for the Treatment of Neoplastic Disease. (granted 12/31/2008)

Burzynski, S.R. Patent No: 229199 A method of preparing 4-phenylbutyric acid. (granted 2/13/2009)

Indonesia

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: ID0012068 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 11/11/2003)

Burzynski, S.R. Patent No: ID0013227 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 4/28/2004)

Burzynski, S.R. Patent No: ID0018257 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 10/30/2006)

Ireland

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Israel

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 65960 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 3/1/1986)

Burzynski, S.R. Patent No: 140848 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 8/18/2005)

Burzynski, S.R. Patent No: 162141 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 8/5/2009)

Burzynski, S.R. Patent No: 158914 Synthesis of 4-phenylbutyric acid. (granted 7/30/2010)

Trademark Patent No: 247442 Fengenal in Class 5 (Trademark 1/1/2015)

Trademark Patent No: 247444 Cengenal in Class 5 (Trademark 1/1/2015)

Trademark Patent No: 247446 Atengenal in Class 5 (Trademark 1/1/2015)

Trademark Patent No: 247447 Avavital in Class 5. (Trademark 1/1/2015)

Trademark Patent No: 247445 Astugenal in Class 5 (Trademark 9/24/2015)

Italy

Burzynski, S.R. Patent No: 0069232 Patent No. National: 22434/BE/86 Pharmaceutical

composition comprising phenylacetylglutamine, a combination of this compound with

phenylacetic acid or 3-(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Patent No. National: 19057/BE/96 Pharmaceutical

compositions for use in treating Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Patent No. National: 26583/BE/9 Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Japan

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 1953215 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 7/28/1995)

Burzynski, S.R. Patent No: 2010265 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 2/2/1996)

Burzynski, S.R. Patent No: 2010676 Process for synthesizing the compound 3-(N-

phenylacetylamino) piperidine-2,6-dion. (granted 2/2/1996)

Burzynski, S.R. Patent No: 2057285 Pharmaceutical compositions for neoplastic disease.

(granted 5/23/1996)

Burzynski, S.R. et al. Patent No: 4320052 Liposomal Antineoplastons Therapies with

Markedly Improved Antineoplastic Activity. (granted 6/5/2009)

Burzynski, S.R. Patent No: 4338401 Synthesis of 4-phenylbutyric acid. (granted 7/10/2009)

Burzynski, S.R. Patent No: 4536258 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 6/25/2010)

Burzynski, S.R. Patent No: 4614660 Formulation of amino acids and riboflavin useful to

reduce toxic effects of cytotoxic chemotherapy. (granted 10/29/2010)

Kazakhstan

Burzynski, S.R. Patent No: 1562 Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. (granted 12/15/1994)

Trademark Patent No: 41909 Aminocare in Class 5 (Trademark 10/22/2013)

Trademark Patent No: 41910 Avavital in Class 5. (Trademark 10/22/2013)

Trademark Patent No: 41911 Atengenal in Class 5. (Trademark 10/22/2013)

Trademark Patent No: 41912 Astugenal in Class 5. (Trademark 10/22/2013)

Trademark Patent No: 41913 Cengenal in Class 5. (Trademark 10/22/2013)

Trademark Patent No: 41914 Fengenal in Class 5. (Trademark 10/22/2013)

Korea

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Latvia

Burzynski, S.R. Patent No: 5474 Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. (granted 3/10/1994)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Lithuania

Burzynski, S.R. Patent No: 3518 Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. (granted 12/27/1996)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Trademark Patent No: 67271 Fengenal in Class 5. (Trademark 8/26/2013)

Trademark Patent No: 67272 Cengenal in Class 5. (Trademark 8/26/2013)

Trademark Patent No: 67273 Astugenal in Class 5. (Trademark 8/26/2013)

Trademark Patent No: 67274 Atengenal in Class 5. (Trademark 8/26/2013)

Trademark Patent No: 67275 Aminocare in Class 5 (Trademark 8/26/2013)

Trademark Patent No: 67562 Avavital in Class 5. (Trademark 8/26/2013)

Luxembourg

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Macau

Trademark Patent No: N/062073 Fengenal in Class 5 (Trademark 8/16/2012)

Trademark Patent No: N/062074 Cengenal in Class 5 (Trademark 8/16/2012)

Trademark Patent No: N/062075 Astugenal in Class 5 (Trademark 8/16/2012)

Trademark Patent No: N/062076 Atengenal in Class 5 (Trademark 8/16/2012)

Trademark Patent No: N/062077 Avavital in Class 5 (Trademark 8/16/2012)

Trademark Patent No: N/062078 Aminocare in Class 5 (Trademark 8/16/2012)

Malaysia

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: MY102918A Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 3/31/1993)

Trademark Patent No: 2012054843 Atengenal in Class 5. (Trademark 11/26/2013)

Trademark Patent No: 2012054844 Avavital in Class 5. (Trademark 11/26/2013)

Trademark Patent No: 2012054846 Fengenal in Class 5. (Trademark 11/26/2013)

Trademark Patent No: 2012054850 Astugenal in Class 5. (Trademark 11/26/2013)

Trademark Patent No: 2012054860 Cengenal in Class 5. (Trademark 11/26/2013)

Mexico

Burzynski, S.R. Patent No: Pending Methods for the Treatment of Leptomeningeal Disease (Pending )

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending )

Burzynski, S.R. Patent No: 222968 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 9/24/2004)

Burzynski, S.R. Patent No: 247856 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 8/6/2007)

Monaco

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Netherlands

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

New Zealand

Burzynski, S.R. Patent No: 200805 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 2/12/1987)

Burzynski, S.R. Patent No: 509244 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 6/8/2004)

Burzynski, S.R. Patent No: 532833 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 4/5/2007)

Norway

Burzynski, S.R. Patent No: 163595 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 7/27/1990)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 332858 Formulation of amino acids and riboflavin useful to reduce toxic effects cytotoxic chemotherapy. (granted 1/21/2013)

Philippines

Burzynski, S.R. Patent No: 26099 Methods for preparing 3-(N-phenylacetyl-

aminopiperidine)-2,6-dion. (granted 2/6/1992)

Burzynski, S.R. Patent No: 28523 Methods for treating Parkinson's disease. (granted

10/11/1994)

Burzynski, S.R. Patent No: 28633 Methods for treating AIDS. (granted 11/21/1994)

Burzynski, S.R. Patent No: 1-2004-500758 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 7/23/2007)

Trademark Patent No: 1598.40.04 Atengenal in Class 5 (Trademark 6/4/2012)

Trademark Patent No: 1598.40.06 Aminocare in Class 5 (Trademark 6/4/2012)

Trademark Patent No: 1598.40.01 Fengenal in Class 5 (Trademark 6/14/2012)

Trademark Patent No: 1598.40.02 Cengenal in Class 5 (Trademark 6/14/2012)

Trademark Patent No: 1598.40.03 Astugenal in Class 5 (Trademark 6/14/2012)

Trademark Patent No: 1598.40.05 Avavital in Class 5 (Trademark 6/14/2012)

Poland

Burzynski, S.R. Patent No: 163552 Methods for preparing 3-(N-phenylacetylamino)

piperidine-2,6-dion. (granted 8/6/1993)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Trademark Patent No: 188750 Lubgen Farma (Trademark 10/9/2007)

Burzynski, S.R., Musial, L. Patent No: 201802 Synthesis of 4-phenylbutyric acid. (granted 9/29/2008)

Burzynski, S.R. Patent No: 213698 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 9/9/2012)

Portugal

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Republic of Korea

Burzynski, S.R. Patent No: 139204 Methods for preparing 3-(N-phenylacetylamino-

piperidine)-2,6-dion. (granted 2/26/1998)

Burzynski, S.R. Patent No: 399658 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 9/17/2003)

Burzynski, S.R. Patent No: 0414587 A Pharmaceutical Composition Comprising

Phenylacetate and Phenylacetylglutamine. (granted 12/26/2003)

Burzynski, S.R. Patent No: 0417100 A Pharmaceutical Composition Comprising

Phenylacetate and Phenylacetylisoglutamine. (granted 1/19/2004)

Burzynski, S.R. Patent No: 0417101 A Pharmaceutical Composition Comprising an Aqueous Solution of Phenylacetate. (granted 1/19/2004)

Trademark Patent No: 620203 Bugenal in Class 5 (Trademark 6/21/2005)

Trademark Patent No: 622094 Astugenal in Class 5 (Trademark 6/21/2005)

Trademark Patent No: 622095 Atengenal in Class 5 (Trademark 6/21/2005)

Trademark Patent No: 622096 Avavital in Class 5 (Trademark 6/21/2005)

Trademark Patent No: 622097 Cengenal in Class 5 (Trademark 6/21/2005)

Trademark Patent No: 622098 Fengenal in Class 5 (Trademark 6/21/2005)

Trademark Patent No: 120234 Lubgen Farma in Class 35 (Arranging of pharmaceuticals sales) (Trademark 8/24/2005)

Trademark Patent No: 129501 Lubgen Farma in Class 40 (custom manufacturing of

pharmaceutical preparations for others) (Trademark 3/20/2006)

Burzynski, S.R. Patent No: 905139 Synthesis of 4-phenylbutyric acid. (granted 6/22/2009)

Burzynski, S.R. Patent No: 953483 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 3/25/2010)

Romania

Burzynski, S.R. Patent No: 121173 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 1/30/2007)

Russia

Burzynski, S.R. Patent No: 1809830 Methods for preparing 3-(N-phenylacetylamino-

piperidine)-2,6-dion. (granted 10/2/1992)

Trademark Patent No: 292206 Astugenal in Class 5 (Trademark 7/11/2005)

Trademark Patent No: 293368 Bugenal in Class 5 (Trademark 8/2/2005)

Trademark Patent No: 300114 Cengenal in Class 5 (Trademark 1/11/2006)

Trademark Patent No: 304514 Lubgen Farma in Class 35 (Arranging of pharmaceuticals sales) and in Class 40 (custom manufacturing of pharmaceutical preparations for others) (Trademark 4/7/2006)

Trademark Patent No: 304679 Avavital in Class 5 (Trademark 4/12/2006)

Trademark Patent No: 304680 Atengenal in Class 5 (Trademark 4/12/2006)

Trademark Patent No: 304681 Fengenal in Class 5 (Trademark 4/12/2006)

Burzynski, S.R., Musial, L. Patent No: 2297998 Synthesis of 4-phenylbutyric acid. (granted 4/27/2007)

Trademark Patent No: 327323 Aminocare in Class 5 (Trademark 5/30/2007)

Singapore

Burzynski, S.R. Patent No: 81891 Compositions and methods for treating autoimmune

diseases. (granted 8/11/2001)

Burzynski, S.R. Patent No: 67344 Methods for treating viral infections. (granted 1/11/2002)

Burzynski, S.R. Patent No: 81889 Pharmaceutical compositions for use in treating AIDS.

(granted 1/29/2002)

Burzynski, S.R. Patent No: 78643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 2/28/2003)

Burzynski, S.R., Musial, L. Patent No: 0101088 Synthesis of 4-phenylbutyric acid. (granted 2/28/2006)

Burzynski, S.R. Patent No: 104603 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 6/30/2006)

Slovenia

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 21542 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 2/28/2005)

South Africa

Burzynski, S.R. Patent No: 82/4178 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 6/29/1983)

Burzynski, S.R. Patent No: 91/6977 Pharmaceutical compositions for use in treating AIDS. (granted 6/24/1992)

Burzynski, S.R. Patent No: 91/7016 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 6/24/1992)

Burzynski, S.R. Patent No: 95/3500 Methods for treating neurofibromatosis. (granted

7/31/1996)

Burzynski, S.R. Patent No: 2001/0622 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 6/26/2002)

Burzynski, S.R. Patent No: 2004/4115 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 11/30/2005)

Spain

Burzynski, S.R. Patent No: 512894 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 10/2/1984)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Patent No. National: 2214866 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Burzynski, S.R. Patent No: 2219102 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 11/16/2004)

Sweden

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Switzerland

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

Taiwan

Burzynski, S.R. Patent No: 42331 Methods for preparing 3-(N-phenylacetylamino-

piperidine)-2,6-dion. (granted 2/21/1991)

Trademark Patent No: 01165897 Aminocare in Class 5 (Trademark 8/1/2005)

Trademark Patent No: 01543739 Fengenal in Class 5 (Trademark 11/1/2012)

Trademark Patent No: 01543740 Cengenal in Class 5 (Trademark 11/1/2012)

Trademark Patent No: 01543741 Astugenal in Class 5 (Trademark 11/1/2012)

Trademark Patent No: 01543742 Atengenal in Class 5 (Trademark 11/1/2012)

Trademark Patent No: 01543743 Avavital in Class 5 (Trademark 11/1/2012)

Thailand

Burzynski, S.R. Patent No: Pending Methods for the treatment of recurrent glioblastoma

(RGBM). (Pending)

Trademark Patent No: 853930 Fengenal in Class 5 (Trademark 10/28/2014)

Trademark Patent No: 853931 Cengenal in Class 5 (Trademark 10/28/2014)

Trademark Patent No: 853933 Atengenal in Class 5 (Trademark 10/28/2014)

Trademark Patent No: 853932 Astugenal in Class 5 (Trademark 1/19/2015)

Ukraine

Burzynski, S.R. Patent No: 15756 Methods for preparing 3-(N-phenylacetylamino-

piperidine)-2,6-dion. (granted 12/12/1996)

Burzynski, S.R. Patent No: 78977 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 5/10/2007)

United Kingdom

Burzynski, S.R. Patent No: 0069232 Pharmaceutical composition comprising

phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-

(phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) piperidine-2, 6-dione. (granted 10/29/1986)

Burzynski, S.R. Patent No: 0197358 Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. (granted 5/23/1990)

Burzynski, S.R. Patent No: 0500901 Pharmaceutical compositions for use in treating

Parkinson's disease. (granted 11/2/1995)

Burzynski, S.R. Patent No: 0500905 Pharmaceutical compositions for use in treating AIDS. (granted 3/13/1996)

Burzynski, S.R. Patent No: 0603383 Compositions and methods for treating autoimmune

diseases. (granted 1/28/1998)

Burzynski, S.R. Patent No: 0680756 Use of a combination of antineoplastons for the

manufacture of a medicament for the treatment of neurofibromatosis. (granted 8/18/1999)

Burzynski, S.R. Patent No: 0601164 Methods for treating viral infections. (granted 1/19/2000)

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Burzynski, S.R. Patent No: 1098643 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 1/7/2004)

USA

Burzynski, S.R. Patent No: Methods for the treatment of glioblastoma multiforme. (pending)

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating breast cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating colorectal cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating head and neck cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating kidney cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating lung cancer. (Pending)

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating ovarian cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating pancreatic cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating prostate cancer. (Pending )

Burzynski, S.R. Patent No: Pending Composition comprising Antineoplastons and methods or treating uncommon cancers. (Pending )

Burzynski, S.R. Patent No: Pending Composition For and Methods of Precision Cancer Treatment.

(Application filed for US and PCT.

Contracting States, out of 157 PCT States, will be selected in the future). (Pending )

Burzynski, S.R. Patent No: 4444890 Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy. (granted 4/24/1984)

Burzynski, S.R. Patent No: 4470970 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 9/11/1984)

Burzynski, S.R. Patent No: 4558057 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 12/10/1985)

Burzynski, S.R. Patent No: 4559325 Purified antineoplaston fractions and methods of treating neoplastic disease. (granted 12/17/1985)

Burzynski, S.R. Patent No: 4593038 Topical use of 3-phenylacetylamino-2, 6-piperidinedione for treatment of skin wrinkles and hyperpigmentation. (granted 6/3/1986)

Burzynski, S.R. Patent No: 4918193 Methods for preparing 3-(N-phenylacetylamino-

piperidine)-2,6-dion. (granted 4/17/1990)

Burzynski, S.R. Patent No: 5089508 Methods for treating AIDS. (granted 2/18/1992)

Burzynski, S.R. Patent No: 5116622 Methods for treating Parkinson's disease. (granted

5/26/1992)

Trademark Patent No: 1719793 Federal trademark 'Antineoplaston' for pharmaceuticals.

(Trademark 9/29/1992)

Burzynski, S.R. Patent No: 5244922 Methods for treating viral infections. (granted 9/14/1993)

Burzynski, S.R. Patent No: 5254587 Methods for treating AIDS. (granted 10/19/1993)

Burzynski, S.R. Patent No: 5391575 Methods for treating neurofibromatosis. (granted

2/21/1995)

Burzynski, S.R. Patent No: 5646182 Methods for treating autoimmune diseases. (granted

7/8/1997)

Burzynski, S.R., Byra, A., Waldbilling, R.J. Patent No: 6013278 Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity. (granted 1/11/2000)

Trademark Patent No: 05059017 State Trademark 'Antineoplaston', Texas. (Trademark

4/11/2000)

Burzynski, S.R. Patent No: 6127419 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. (granted 10/3/2000)

Burzynski, S.R. Patent No: 6258849 B1 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 7/10/2001)

Burzynski, S.R., Musial, L. Patent No: 6372938 B1 Synthesis of 4-phenylbutyric acid.

(granted 4/16/2002)

Burzynski, S.R. Patent No: 6943192 B2 Treatment regimen for administration of

phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. (granted 9/13/2005)

Trademark Patent No: 2999213 Bugenal in Class 5 (Trademark 9/20/2005)

Burzynski, S.R. Patent No: 6987131 Phenylacetic Acid Compositions for Treating or

Preventing Hypercholesterolemia. (granted 1/17/2006)

Burzynski, S.R., Gruszecki, W. Patent No: 7087219 Toothpaste Containing Anticancer

Agents. (granted 8/8/2006)

Trademark Patent No: 3142996 Ampolgen Pharmaceuticals, LLC. In Classes 35 and 42.

(Trademark 9/12/2006)

Trademark Patent No: 3160376 Aminocare in Class 6 (Trademark 10/17/2006)

Trademark Patent No: 3169436 Avavital in Class 5 (Trademark 11/7/2006)

Trademark Patent No: 3174860 Fengenal in Class 5 (Trademark 11/21/2006)

Trademark Patent No: 3177785 Astugenal in Class 5 (Trademark 11/28/2006)

Trademark Patent No: 318432 Atengenal in Class 5 (Trademark 12/12/2006)

Trademark Patent No: 3276180 Cengenal in Class 5 (Trademark 8/7/2007)

Burzynski, S.R. Patent No: 7427619 B2 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. (granted 9/23/2008)

Burzynski, S.R. Patent No: 10624869 B2 Methods for the treatment of recurrent glioblastoma (RGBM). (granted 4/21/2020)

Burzynski, S.R. Patent No: 11234951 B2 Methods for the treatment of glioblastoma

multiforme. (granted 2/1/2022)

Burzynski, S.R. Patent No: 11344521 Methods for the Treatment of Leptomeningeal Disease (granted 5/31/2022)

Vietnam

Trademark Patent No: 200989 Cengenal in Class 5 (Trademark 2/28/2013)

Trademark Patent No: 200990 Astugenal in Class 5. (Trademark 2/28/2013)

Trademark Patent No: 200991 Atengenal in Class 5 (Trademark 2/28/2013)

Trademark Patent No: 200992 Avavital in Class 5. (Trademark 2/28/2013)

Trademark Patent No: 205522 Fengenal in Class 5 (Trademark 5/14/2013)

WIPO

Burzynski, S.R. Patent No: Pending Compositions for and methods of precision cancer treatment.

Contracting States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, EH, EN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW (pending )

Trademark Patent No: 787094 AMINOCARE (Trademark 8/14/2002)

Stanislaw R. Burzynski MD, PhD and Founder

About The Doctor

CURRICULUM VITAE

Stanislaw R. Burzynski, M.D., Ph.D.

POSITIONS HELD

SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS

RESEARCH SUPPORT

HONORS AND AWARDS

More Information About Stanislaw R. Burzynski MD, PHD

BURZYNSKI CLINIC

PATIENT RESOURCES

LEARN MORE

INFO